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Abstract
 
Circulatory noncoding small RNAs (miRNAs), which are present in various body 
fluids, are reported to be potentially used as biomarkers for disease and pregnancy. The 
present study was conducted to investigate the effect of ovarian hyperstimulation on the 
expression pattern of circulatory miRNA in follicular fluid and blood plasma. For this, 
Simmental heifers (n=12) were synchronized using a standard synchronization protocol 
and six of them were hyperstimulated using FSH. Following this, whole blood samples 
were collected at day 0 (onset of oestrous), 3 and 7, follicular fluid samples were 
aspirated from dominant follicles at the day 0 from all animals by ovum pickup. Total 
RNA including miRNA was isolated from plasma samples of both groups at day 7 and 
follicular fluid at day 0. Subsequent expression profiling of miRNA was performed 
using the human miRCURY LNA™ Universal RT miRNA PCR array platform with 
745 miRNA primer assays. Of the 24 miRNAs, which were differentially expressed in 
blood plasma between hyperstimulated and unstimulated animals, 9 miRNAs including 
miR-127-3p, miR-494, miR-147, miR-134 and miR-153 were down regulated and 15 
miRNAs including miR-34a, miR-103, let-7g, miR-221 were found to be up regulated 
in the hyperstimulated  animals. Similarly, 66 miRNAs were found to be differentially 
expressed in follicular fluid derived from hyperstimulated and unstimulated groups. Out 
of these, while 32 miRNAs were down regulated, 34 were up regulated in follicular 
fluid aspirated from hyperstimulated animals. Ingenuity pathway analysis (IPA) of 
potential target genes of candidate miRNAs, which are dysregulated due to ovarian 
hyperstimulation, revealed axonal guidance signaling and Wnt ß-catenin signaling 
pathways to be the dominant ones. In conclusion, this study revealed ovarian 
hyperstimulation resulted in changes in expression profile of circulatory miRNA in 
blood and follicular fluid.  
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Zusammenfassung 
 
Zirkulierende nicht-kodierende micro RNAs (miRNAs), die in verschiedenen 
Körperflüssigkeiten vorhanden sind, sind möglicherweise potenzielle Biomarker für 
Krankheiten und Trächtigkeit. Die vorliegende Studie wurde durchgeführt, um die 
Wirkung einer ovarialen Überstimulation auf das Expressionsmuster von zirkulierenden 
miRNAs in der Follikelflüssigkeit und im Blutplasma zu untersuchen. Dazu wurden 
Fleckvieh-Färsen (n=12) mit einem Standard-Synchronisationsprotokoll synchronisiert 
und sechs von ihnen mit FSH überstimuliert. Die Probenentnahme beinhaltete 
Blutproben zum Zeitpunkt 0 (Beginn der Brunst), am 3. und am 7. Tag sowie die 
Follikelflüssigkeit von dominanten Follikel am Tag 0 von allen Tieren durch „Ovum 
pickup”. Die Gesamt-RNA inklusive der miRNAs wurde aus den Plasmaproben von 
beiden Gruppen an Tag 7 und aus der Follikelflüssigkeit am Tag 0 isoliert. Das 
nachfolgende Expressionprofiling der miRNAs erfolgte unter Verwendung der 
Humanen miRCURY LNA ™ Universal-RT-PCR- miRNA-Array-Plattform mit 745 
miRNA Primer-Assays. Von den 24 miRNAs, die im Blutplasma beim Vergleich 
zwischen hyperstimulierten und unstimulierten Tieren unterschiedlich exprimiert waren, 
zeigten 9 miRNAs, einschließlich miR-127-3p, miR-494, miR-147, miR-134 und miR-
153, eine Runterregulation, während 15 miRNAs einschließlich miR-34a, miR-103 , let-
7g, miR-221 eine erhöhte Expression  in den hyperstimulierten Tieren aufwiesen. Des 
Weiteren, konnten beim Vergleich der Follikelflüssigkeit von hyperstimulierten und 
unstimulierten Tieren 66 differentiell exprimierte miRNAs identifiziert werden. Von 
diesen waren 32 miRNAs herunterreguliert, während 34 in der Gruppe der 
hyperstimulierten Tiere raufreguliert waren. Eine Ingenuity Pathway Analyse (IPA) der 
potentiellen Zielgene von Kandidaten miRNAs, die aufgrund von Überstimulation der 
Ovarien eine Fehlregulation zeigten,  ergab als dominante Signalwege die axonale 
Führung sowie Wnt-ß-Catenin. Die Ergebnisse dieser Studie zeigte, dass eine 
Überstimulation der Ovarien zu Veränderungen im Expressionsprofil von 
zirkulierenden miRNAs im Blut und in der Follikelflüssigkeit führte.
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1 Introduction 
 
Controlled ovarian hyperstimulation (COH) stimulates the ovaries by 
supraphysiological levels of gonadotropins to growth multiple follicle in single 
ovulation species including humans and bovine. In bovine, in order to expand the 
number of offspring during the lifetime of an individual, female animals with high 
genetic value are typically stimulated with gonadotropins hormones to persuade the 
ovulation of a variable number of follicles. Similarly, women undergoing IVF treatment 
undergo COH to induce the development of multiple dominant follicles. 
 
For several years, the most common use of embryo transfer has benefited from the 
establishment of newer, more efficient methods for the superovulation of donors, 
embryo retrieval ⁄ transfer by low-invasive methods as well as by the better, simpler and 
more effective cryopreservation methods in human and bovine. However, despite 
significant advances in assisted reproduction technology protocols in humans and 
bovine, pregnancy rates are still relatively low and have not increased significantly in 
the last decade (Andersen et al. 2007). On another hand an increase in chromosomal 
abnormalities has been reported in human embryos after conventional stimulation, 
mainly resulting from an increased incidence of chromosome segregation errors during 
the first embryonic divisions, and abnormalities were lowest in embryos which divided 
within the expected physiological time frame (Baart et al. 2009). The changes in the 
oviduct and uterine environment related to hormonal treatments and subsequent 
influence on the transcriptome profile of embryos have been investigated (Gad et al. 
2011). The potential implications of circulating progesterone on the composition of 
oviduct and uterine fluid are interesting but data on the composition of these fluids are 
sparse (Hugentobler et al. 2007, Hugentobler et al. 2008). It is well known that 
controlled ovarian hyperstimulation  leads to deviant oocyte maturation in the follicle 
(Hyttel et al. 1989) as well as an abnormal endocrine environment in the reproductive 
tract.  
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Follicle development in the ovary consists of the growth of competent follicles, the 
division of granulosa cells, the expansion of the follicular basal lamina, and finally, the 
formation of the follicular fluid in the follicular antrum  (Fortune 1994). Follicular fluid 
consists of secretions from the granulosa and thecal cells combined with plasma 
components that cross the blood-follicular barrier via the thecal capillaries (Rodgers and 
Irving-Rodgers 2010). This fluid provides a very important microenvironment and 
contains regulatory molecules that are important for the maturation and quality of the 
oocytes (Revelli et al. 2009). Certain lipids, proteins, vitamins, and metabolites in the 
follicular fluid have been found to be associated with reproductive diseases (Kim et al. 
2006), oocyte quality (Berker et al. 2009), embryo quality, and the outcome of in vitro 
fertilization attempts  (Wallace et al. 2012, Wu et al. 2007). 
 
 Follicular development, a coordinated and bidirectional communication mediated by a 
large number of gene products and the expression of these genes must be meticulous 
and well timed. Gene expression is a highly complex process controlled at 
transcriptional and translational levels. MicroRNAs are noncoding small RNAs which 
are known to play roles in posttranscriptional regulation of genes involved in various 
physiological processes in female reproduction. MicroRNAs are endogenous small 
noncoding RNAs that regulate the activities of target mRNAs by binding at sites in the 
3' untranslated region of the mRNAs (Ambros 2001, Bartel 2004).Many studies showed 
the role of miRNAs in follicular development, oocyte maturation, peri-implantation and 
pre-implantation periods (Lei et al. 2010, Mondou et al. 2012) by regulating gene 
expression at the  transcriptional level.  Currently 783 bovine miRNAs are registered 
(miRBase 2013) and more than 3000 validated targets (miRecords 2013). 
 
Circulating RNAs have been shown to be useful biomarkers for multiple clinical 
endpoints including the diagnosis of preeclampsia (Freeman et al. 2008), the diagnosis 
and monitoring of diabetic retinopathy (Shalchi et al. 2008) and neuropathy (Sandhu et 
al. 2008), and as diagnostic or prognostic markers for multiple cancers (Dasi et al. 2001, 
Kopreski et al. 1999, Mitchell et al. 2008, Rabinowits et al. 2009, Taylor and Gercel-
Taylor 2008). Cellular release of miRNA molecules into the circulation has been shown 
to occur through multiple mechanisms. Among passive processes, the release of cellular 
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miRNA has been shown following necrotic cell death (Rainer et al. 2004). Among 
active processes, miRNA molecules have been identified coupled by exosomes (Valadi 
et al. 2007), high-density lipoprotein (HDL) (Vickers et al. 2011), Ago2 complex 
(Arroyo et al. 2011), shedding vesicles (Cocucci et al. 2009) and apoptotic blebs 
(Halicka et al. 2000). The function of exosomes, HDL and shedding vesicles are 
believed to be cell-to-cell communication and can be used as platforms for multi 
signalling processes (Cocucci et al. 2009, Halicka et al. 2000, Vickers et al. 2011).  
 
To our knowledge, effects of hormonal treatment on circulating miRNA profile have 
not been investigated yet therefore this study is novel study to find a key 
tophysiological changes induced by controlled ovarian hyperstimulation in steroid 
hormones target tissues.  Also in this work, we addressed questions regarding, possible 
origin and biological function of circulating extracellular miRNA in bovine follicular 
fluid and blood plasma. Taking all promising information together, this experiment has 
been conducted to find effects of ovarian hyperstimulation on the expression profile of 
circulatory miRNAs in follicular fluid and blood plasma, investigation of temporal 
circulatory miRNA expression during oestrus days and characterization plasma and 
follicular fluid circulatory miRNA transportation with exosomes or the Ago2 complex.  
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2 Literature review   
2.1 Folliculogenesis  
The mammalian ovary is an extremely dynamic organ with sequential waves of 
follicular growth and regression, rupture of mature follicles at the adjacent ovarian wall 
during ovulation, repair of the ovulation wound and the formation of fully functional 
corpora lutea followed by its demise a few days later. This occurs within relatively short 
cycles and under tight hormonal regulation throughout a female's reproductive life 
(Donadeu et al. 2012). Folliculogenesis is the biological developmental process in 
which an activated primordial follicle develops to be a preovulatory follicle following 
the growth and differentiation of the oocyte and its surrounding granulosa cells (Figure 
2.1) (Gougeon 1996, Knight and Glister 2001). During  folliculogenesis, a follicle  may  
be  classified as primordial, primary, secondary or tertiary (Pedersen and Peters 1968).  
The large population of non-growing primordial follicles serves as the source of 
developing follicles and oocytes until the end of a female’s reproductive life (Eppig 
2001). When granulosa cells surrounding the oocytes change in shape from flattened 
to cuboidal and the oocyte begin its extensive growth phase, the primordial follicles are 
transformed into primary follicles (van Wezel and Rodgers 1996). 
 
The initial stages of folliculogenesis occur independently of gonadotrophic hormones. 
Antral follicles initially become responsive to and then dependent on FSH. There are 
continual transient increases in FSH in cattle during the oestrous cycle and anoestrus 
which cause the recurrent emergence and development of cohorts of follicles (Roche 
1996). The transition to antral follicle is characterized by formation of antrum which is 
a fluid filled cavity surrounded by multiple layer of granulosa cell; this fluid contain 
important regulatory substance to be delivered to oocyte (Braw-Tal and Yossefi 1997, 
Eppig 2001). After antrum formation, granulosa cells are divided into two distinct 
subtypes, the cumulus granulosa surrounding and in intimate metabolic contact with the 
oocyte forming a structure called cumulus oocyte complex (COC) and the mural 
granulosa lining the follicle wall adjacent to the basal lamina. The mural granulosa cells 
nearest the antrum are called periantral granulosa cells (Eppig 2001). 
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Figure 2.1 Schematic representation of ovarian events and associated changes in 
circulating hormone levels during an ovulatory cycle as exemplified by the bovine 
(Donadeu et al. 2012). 
 
 
Finally, in response to preovulatory gonadotrophins surge, two marked events occur in 
cumulus oocyte complex: 
A. The fully grown oocyte resume meiosis to complete first meiotic division via 
germinal vesicle break down, chromatin re-condensation, the pairs of homologous 
chromosomes are separated and half of them are expelled forming the first polar body 
and the mature oocyte is arrested again in metaphase of second meiotic division  B. The 
cumulus cell surrounding the oocyte undergo expansion or mucification through 
secretion of hyaluronic acid, a nonsulphated glycosaminoglycan bound to the cumulus 
cells by linker proteins (Buccione et al. 1990, Chen et al. 1996, Eppig 1979, Salustri et 
al. 1989) and when the hyaluronic acid becomes hydrated, the spaces between cumulus 
cells become enlarged and the cells become embedded in a sticky mucified matrix. If 
cumulus expansion is suppressed, ovulation rate is greatly reduced (Chen et al. 1993). 
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After ovulation, the rest of follicle developed into corpus luteum which is a highly 
vascularised endocrine organ producing progesterone hormone which is essential for the 
maintenance of pregnancy. 
 
2.2 Follicular fluid 
 
Follicular fluid provides a very important microenvironment for the development of 
oocytes. Follicular fluid is a product of both the transfer of blood plasma constituents 
that cross the blood follicular barrier and of the secretory activity of granulosa and 
thecal cells (Fortune 1994). It is reasonable to hypothesise that some biochemical 
characteristics of the follicular fluid circumfluenting the oocyte may play a critical role 
in oocyte quality index and the subsequent potential to achieve fertilization and embryo 
development. The analysis of follicular fluid components may also provide information 
on metabolic changes in blood serum, as the circulating biochemical milieu may be 
reflected in the composition of follicular fluid (Leroy et al. 2004). Follicular fluid is 
easily available as it is aspirated together with the oocyte at the time of oocyte pick up. 
In the last years, the studies of follicular fluid contents has been conducted by assaying 
one or more substances in the fluid derived from individual follicles and by relating it to 
the fate of the oocyte from that specific follicle (Revelli et al. 2009). In fact, the 
composition of follicular fluid is similar to serum with respect to low-molecular-weight 
components, with most electrolytes being at the same concentrations in fluid and serum 
(Gosden et al. 1988, Rodgers and Irving-Rodgers 2010, Shalgi et al. 1973). 
 
2.3 Follicular fluid content and oocyte quality 
 
The rate at which the follicular antrum expands and follicular fluid accumulates differs 
between follicles, particularly between dominant and subordinate follicles (Beg et al. 
2001, Fortune et al. 1991). The proportion of a follicle that is follicular fluid at 
maximum size also varies from species to species. Generally, larger species such as 
ovine, equine, porcine, human, and bovine have larger follicles, with the fluid 
comprising a substantial proportion of the volume of the follicles at ovulation 
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(estimated at >95% in bovine) (Beg et al. 2001, Rodgers and Irving-Rodgers 2010). 
Smaller species such as rats and mice have smaller follicles with fractionally less 
follicular fluid (Rodgers and Irving-Rodgers 2010). A clear correspondence between 
specific follicular fluid biochemical characteristics and measurable oocyte quality 
linked, embryo-related variables has not been established to date. In the last years, the 
research in this area has progressed toward a more complex type of molecular analysis, 
metabolomics, which is the analysis of all substances contained in a biological fluid 
(Figure 2.2). The chemical constituents of follicular fluid  have been grouped in the 
following categories: 1) hormones; 2) growth factors of the Transforming Growth 
Factor-beta superfamily; 3) other growth factors and interleukins; 4) reactive oxygen 
species; 5) anti-apoptotic factors; 6) proteins, peptides and amino-acids; 7) sugars; 8) 
prostanoids. 
 
 
Figure 2.2 Drawing illustrating the routes fluid can take from the thecal capillary to the 
follicular fluid and the potential barriers of the endothelium, subendothelial basal 
lamina, interstitium, follicular basal lamina, and membrana granulosa. Routes 1 and 3 
show movement of fluid between the cells (solid arrows), and routes 2 and 4 show 
transcellular routes (hatched arrows) that either involve aquaporins or transcytosis and 
follicular fluid biochemical modified from (Rodgers and Irving-Rodgers 2010). 
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2.3.1 Gonadotrophins 
 
It becomes evident that gonadotropins play an important role in the secretion of several 
substances by granulosa cells (e.g. hyaluronic acid), in turn affecting oocyte 
development and maturation. They may also act synergistically with estradiol (E2) in 
enhancing cytoplasmic maturation of the oocyte and, via cyclic AMP (cAMP) secretion, 
control oocyte meiosis: higher levels of gonadotropins would improve these processes 
and lead to better oocytes, better embryos and improved pregnancy rate (Revelli et al. 
2009). Notably, GH seems to play a similar (and may be synergic with gonadotropins) 
role (Mendoza et al. 2002). Intrafollicular titers of FSH and LH are affected by their 
circulating levels: in IVF cycles, the serum levels are determined by the amount of 
exogenously administered gonadotrophins and by the degree of pituitary suppression 
(relevantly reducing the endogenous gonadotropin secretion). High follicular fluid titers 
of FSH (Suchanek et al. 1988), hCG (Ellsworth et al. 1984), and LH (Cha et al. 1986) 
have been reported to promote oocyte maturation and to be associated with oocyte 
having a high chance of fertilization (Revelli et al. 2009). These data was confirmed by 
immunohistochemistry studies that stained granulosa cells for hCG: oocytes that 
subsequently had fertilized had, in fact, had significantly more granulosa cells 
immunobound to hCG than non-fertilizable oocytes (Enien et al. 1998). Follicular fluid 
LH was observed to be consistently higher in follicles containing oocytes that resulted 
in embryos leading to successful IVF attempts (Mendoza et al. 2002). 
 
2.3.2 Steroid hormones  
 
It is well known that a predominantly intrafollicular estrogenic environment is 
associated with good follicular growth and has anti-atresia effects(Revelli et al. 2009). 
In addition, estrogen enhances the cytoplasmic maturation of oocytes via a direct non-
genomic action at the plasma membrane level, in turn inducing extracellular calcium 
influx into the cell and a specific pattern of Ca2+ oscillations (Tesarik and Mendoza 
1997). Elevated estrogen and estrogen/progesterone ratio in follicular fluid indicate a 
more advanced stage of oocyte maturation and has been repeatedly found to be 
associated with a higher chance of achieving pregnancy (Botero-Ruiz et al. 1984, Lee et 
Literature review    10 
 
al. 1987, Subramanian et al. 1988, Tarlatzis et al. 1985, Tarlatzis et al. 1993, Teissier et 
al. 2000). This observation, however, was not confirmed by other studies (Berger et al. 
1987, Costa et al. 2004, Messinis and Templeton 1987, Rosenbusch et al. 1992, 
Suchanek et al. 1988) . 
 
There is also conflicting evidence regarding the meaning of progesterone levels in 
follicular fluid. Several authors found that a high follicular fluid progesterone 
concentration (or a low E2/P ratio) was predictive of subsequent implantation and 
pregnancy (Basuray et al. 1988, Enien et al. 1995, Kobayashi et al. 1991, Vanluchene et 
al. 1991), and considered it as a reflection of progressive follicle luteinization and 
reduction of aromatase activity linked to the achievement of the final oocyte  
maturation. On the other side, however, oocytes from follicles having high follicular 
fluid P4 were frequently found in association with postmature oocytes that fertilized 
abnormally and gave rise to multipronuclear embryos (Ben-Rafael et al. 1987).  
 
It seems that while an optimal exposure to progesterone has positive effects over oocyte 
characteristics, an excessive exposure leads to a rapid worsening of the cell's quality; a 
clear knowledge of the threshold at which P begins to damage the oocyte is presently 
lacking. Elevated follicular fluid androgen levels (testosterone) were associated with 
lower quality oocytes, and in particular with oocytes showing a trend toward lower 
cleavage rates after fertilization(Uehara et al. 1985). Estrogen/testosterone ratio was 
also reported to be higher in pregnancy-associated follicles (Andersen 1993, Xia and 
Younglai 2000). Taken together, these data seem to indicate that a low 
estrogen/androgen ratio in follicular fluid  may be associated with early follicular 
atresia, which negatively affects the viability of the enclosed oocyte and limits the 
chances of fertilization and pregnancy. Indeed, the notion that a predominantly 
androgenic intrafollicular environment may lead to follicular atresia is well accepted, 
but at the same time it is widely accepted that a certain amount of intrafollicular 
androgens is needed to obtain optimal follicular growth(Revelli et al. 2009). 
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2.4 miRNAs in the embryo produced by assisted reproductive technologies 
Assisted reproductive technology (ART) is the application of laboratory or clinical 
technology to gametes (oocyte or sperm) and/or embryos for the purposes of 
reproduction. These include artificial insemination (AI), embryo transfer (ET), embryo 
production in vitro (IVF), somatic cell nuclear transfer (SCNT and multiplication 
techniques (cloning) for the application of transgenesis animals. The female 
contribution to genetic progress was increased with the advent of embryo transfer and 
the associated techniques such as non-invasive surgery embryo collection, in vitro 
maturation, fertilization and culturing of bovine oocytes. Dams can be super-ovulated, 
artificial insemination and later the resulted embryos are collected by flushing. These 
embryos are then implanted in to synchronized heifers. This technique is referred as 
multiple ovulation and embryo transfer (MOET). Establishment of more efficient 
methods for the bovine ovarian hyperstimulation  of donors, embryo retrieval ⁄ transfer 
by low-invasive methods as well as by the better, simpler and more effective 
cryopreservation methods made public for embryo transfer (Rodriguez-Martinez 2012).  
 
The IVF and SCNT technology has opened the possibilities to manipulate and cultivate 
the embryo. However, it has also been linked to many abnormalities in embryo 
development. Well evident abnormalities in foetuses or calves following transfer of in 
vitro cultivated embryos  includes lower pregnancy rate, increased abortion, oversized 
calves (Allen et al. 2006, Hashimoto et al. 2013, Schurmann et al. 2006, Shevell et al. 
2005), musculoskeletal deformities and abnormalities of placental development, which 
are often described as “Large Offspring Syndrome” (LOS). LOS has been described for 
bovine (Farin et al. 2006), sheep (Sinclair et al. 1999) and mice et (Eggan et al. 2001). 
The abnormalities associated to the IVF, SCNT and in vitro culture of embryo are in 
principle due to aberrant or alteration of transcriptional activity at sub-cellular level 
(Schurmann et al. 2006). Several lines of evidence in mouse and cattle indicate that 
expression patterns of genes from in vitro-produced embryos are not necessarily 
representative of those of in vivo embryos (Niemann and Wrenzycki 2000). Connexin-
43 , crucial for maintenance of compaction , has been found to be expressed by in vivo-
derived bovine blastocysts, but not in their in vitro-produced counterparts (Niemann and 
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Wrenzycki 2000). The bovine leukemia inhibitory factor (bLIF) and LIF-receptor-R 
(LR-8) genes were found to be expressed by in vitro produced embryos, but not in their 
in vivo counterparts. The heat shock protein gene 70.1 (Hsp70.1) has been found 
upregulated by blastocysts produced in vitro compared to in vivo embryos, while the 
glucose transporter-l mRNA (Glut-l) is downregulated by morulae produced in vitro as 
compared to in vivo-derived morulae (Niemann and Wrenzycki 2000). 
 
Candidate gene studies reveal that the failure of implantation may be due to aberrant 
expression of genes in the preimplantation cloned embryo, which are crucial for the 
early regulation and differentiation of the placenta (Hall et al. 2005). At the cellular 
level, a higher incidence of apoptosis (Park et al. 2004a) and aberrant allocation of inner 
cell mass (ICM) (Koo et al. 2002)  is evident. At the sub-cellular level, aberrant DNA 
methylation patterns (Bourc'his et al. 2001) and the dysregulation of genes occurs 
(Humpherys et al. 2002). These abnormalities are thought to mainly be due to 
epigenetic defects (changes in chromatin structure, not involving a change in DNA base 
sequence) which occur during cell reprogramming, where the donor cell DNA is 
reprogrammed by the oocyte cytoplasm to an embryonic state (Schurmann et al. 2006). 
Recent global gene expression profiling study has also evidenced aberrant regulation of 
gene expression either by genetic or epigenetic modification due to manipulation and 
culture of preimplantation embryos (Aston et al. 2009, Gad et al. 2011, Zhou et al. 
2008). According to the nature and extent of regulatory mechanisms it could be 
considered that miRNAs are playing pivotal roles in such aberrant transcriptional 
processes. Since, miRNA has been appeared as first and foremost epigenomic tool or 
modifier that regulate gene expression epigenetically at the post-transcriptional or 
transcriptional level and were found to play important roles during mammalian 
development (Ambros and Lee 2004, Bartel 2004, Kloosterman and Plasterk 2006). 
They were found to be targeted by epigenetic modification and eventually controlling 
epigenetics and some imprinted miRNAs were found to undergo subsequent epigenetic 
reprogramming in mouse embryos (Cui et al. 2009, Kircher et al. 2008, Williams et al. 
2007). Among them, one has revealed the disregulated expression of several miRNAs in 
bovine cloned elongated embryos using a heterologous microarray (Castro et al. 2010). 
miRNAs expression profiling in elongated cloned and in vitro-fertilized bovine embryos 
has suggested that the different state of reprogramming of miRNAs occurred in cloned 
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bovine elongated embryos (Castro et al. 2010). Among the most notable downregulated 
miRNAs found in their study were miR-30d and miR-26a. Both of these miRNAs 
interacted with TKDP, which is involved in maternal recognition of pregnancy in cattle 
(Lagos-Quintana et al. 2001).  
 
2.5 Circulating miRNA in the biological fluids  
Cellular release of RNA molecules into the biological fluids circulation has been 
demonstrated to occur through multiple mechanisms (Figure 2.3). Among passive 
processes, the release of cellular messenger RNA (mRNA) and miRNA has been shown 
following necrotic cell death (Melkonyan et al. 2008, Rainer et al. 2004). After first 
reports of extracellular RNA  published in 1970s (Kamm and Smith 1972, Stroun et al. 
1977), most investigators doubted that extracellular RNA could survive in the blood 
because of the presence of potent ribonucleases (El-Hefnawy et al. 2004). Though, more 
recent studies have published the presence of circulating extracellular RNA in plasma or 
serum, and it has also been demonesterd  that this RNA is protected from plasma RNase 
activity (El-Hefnawy et al. 2004, Tsui et al. 2002). Circulating RNAs have been shown 
to be useful biomarkers for multiple clinical endpoints including mortality in acute 
trauma patients (Rainer et al. 2004), the diagnosis of preeclampsia (Freeman et al. 
2008), the diagnosis and monitoring of diabetic retinopathy and  neuropathy (Shalchi et 
al. 2008) and as diagnostic or prognostic markers for multiple cancers (Dasi et al. 2001, 
Kopreski et al. 1999, Mitchell et al. 2008, Rabinowits et al. 2009, Taylor and Gercel-
Taylor 2008).  
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Figure 2.3 After being transcribed in the nucleus, pre-miRNA molecules can be 
processed further by Dicer in the cytoplasm. In addition, based on recent findings 
(Arroyo et al. 2011; Kosaka et al. 2010; Pigati et al. 2010; Valadi et al. 2007; Vickers et 
al. 2011; Wang et al. 2010), there are at least two ways that pre-miRNAs can be 
packaged and transported using exosomes and MVBs or other (not fully explored) 
pathways together with RNA-binding proteins. After fusion with the plasma membrane, 
MVBs release exosomes into the circulating compartments and bloodstream. Likewise, 
pre-miRNA inside the donor cell can be stably exported in conjunction with RNA-
binding proteins, such as NPM1 (Wang et al. 2010) and Ago2 (Arroyo et al. 2011) or by 
HDL (Vickers et al. 2011). Circulating miRNAs enter the bloodstream and are taken up 
by the recipient cells by endocytosis or, hypothetically, by binding to receptors present 
at the recipient cellular membrane capable of recognizing RNA-binding proteins. More 
studies are necessary to elucidate how miRNAs are loaded into exosomes and how they 
can be internalized by recipient cells. Exosomal miRNAs are processed by the same 
machinery used in miRNA biogenesis and thus have widespread consequences within 
the cell by inhibiting the expression of target protein-coding genes (Cortez et al. 2011). 
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2.6  Characterization of miRNAs in biological fluids  
Serum and plasma contain a large number of miRNAs, serum miRNAs remained stable 
after being subjected to severe conditions, such as boiling, very low or high pH, 
extended storage, and 10 freeze-thaw cycles, conditions that would normally degrade 
most RNAs (Chen et al. 2008). Many theories have attempted to explain the possible 
biological mechanisms by which RNA is preserved from plasma RNase activity 
digestion. One theory explained that RNAs may anneal with DNA, which would render 
them resistant to both RNase and DNase activity (Sisco 2001). Though, evidence  
showed that RNA present in plasma is protected from degradation not by binding to 
DNA, but probably by inclusion in lipid or lipoprotein complexes (El-Hefnawy et al. 
2004).  
 
The RNA molecules enter the circulation are either associated with cellular debris or in 
naked form (Rainer et al. 2004). Among active processes, mRNA and miRNA 
molecules have been identified (Figure 2.4) within membrane-encapsulated vesicles 
released by cells. These include shedding vesicles (Cocucci et al. 2009), exosomes 
(Valadi et al. 2007), high density lipoprotein (HDL) (Vickers et al. 2011)   and 
apoptotic blebs (Halicka et al. 2000). Exosomes are small vesicles (40-100 nm) that are 
formed by inward budding of endosomal membranes (Pan and Johnstone 1983). The 
vesicles are packaged within larger intracellular multivesicular bodies that release their 
contents to the extracellular environment through exocytosis. Shedding vesicles (<200 
nm) are released from live cells through direct budding from the plasma membrane 
(Cocucci et al. 2009), whereas apoptotic blebs (100 to >1,000 nm) bud directly from the 
plasma membrane upon cell death (Simpson et al. 2009). After release from the cell, 
exosomes, shedding vesicles, and apoptotic blebs circulate in the extracellular space, 
where most are broken down within minutes due to the display of phosphatidylserine on 
the external side of the membrane (Cocucci et al. 2009, Fadok et al. 1992).  A fraction 
of the vesicles moves by diffusion into the circulation and appear in biological fluids. 
The function of exosomes and shedding vesicles are believed to be cell-to-cell 
communication and platforms for multisignaling processes (Cocucci et al. 2009, 
Simpson et al. 2009). Although exosomes and shedding vesicles are released in healthy 
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individuals, many pathological conditions and cellular perturbations stimulate further 
release of the particles (Cocucci et al. 2009, Simpson et al. 2009). 
 
 
Figure 2.4 The three types of membranous vesicles that contain extracellular miRNA 
are apoptotic bodies, shedding vesicles, and exosomes (Hunter et al. 2008, Valadi et al. 
2007, Zernecke et al. 2009). Besides these, extracellular miRNA can also be vesicle free 
and associated with either AGO proteins alone or be incorporated into HDL particles 
(Arroyo et al. 2011, Turchinovich et al. 2011, Vickers et al. 2011). Apoptotic bodies can 
contain various cellular organelles including mitochondria and nuclei. Shedding 
vesicles and exosomes both belong to the class of microvesicles and are limited by a 
lipid bilayer. It remains unknown whether microvesicles can also contain pre-miRNA or 
protein-free mature miRNA (question marks). It is also not clear whether miRNA is 
incorporated inside high-density lipoprotein particles or adsorbed on their surface 
(question marks)(Turchinovich et al. 2012). 
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Additionally, it has been hypothesised  that miRNAs, mRNAs and proteins are 
transferred by exosomal signaling in the nervous system (Smalheiser 2007) and in 
embryonic stem cells microvesicles in vitro (Ratajczak et al. 2006, Yuan et al. 2009). 
Other authors demonstrated that miRNA contained in tumor exosomes is functional and 
can suppress the mRNA that encodes signal transduction components within T-cells 
(Taylor and Gercel-Taylor 2008). The same study reported an miRNA signature of 
circulating ovarian cancer exosomes that had a high correlation with primary tumor 
miRNA expression (Taylor and Gercel-Taylor 2008). They found, these miRNAs were 
identified at lower levels coupled with exosomes from women with benign disease and 
were not detected in normal controls. As well as, Rabinowits et al. demonstrated a 
significant difference in exosomal miRNA expression levels between patients with lung 
adenocarcinoma and patients without this disease (Rabinowits et al. 2009). Also, they 
showed a similarity in miRNA signatures between circulating exosomal miRNA and 
originating tumor cells (Rabinowits et al. 2009). In addition, exosomes released by 
glioblastoma cells containing mRNA, miRNA, and angiogenic proteins are taken up by 
normal recipient cells, such as brain microvascular endothelial cells.  
 
Consistent with these observations, these results indicate that cancer patients present 
elevated levels of tumor-derived exosomes in plasma compared with controls. Although 
normal cells within the peripheral circulation can contribute to exosome population, the 
primary source of circulating exosomes in cancer patients is the tumor (Resnick et al. 
2009). Messages delivered by tumor-derived exosomes are translated by recipient cells 
and stimulate proliferation of a human glioma cell line (Skog et al. 2008). Further, the 
tumor-specific epidermal growth factor receptor vIII was detected in serum exosomes 
from 7 of 25 glioblastoma patients (Skog et al. 2008). miR-21, known to be 
overexpressed in glioblastoma tumors (Chan et al. 2005), was elevated in serum 
microvesicles from glioblastoma patients. Moreover, mRNA and miRNA containing 
tumor-derived exosomes can affect biological processes inside of recipient cells. Still, 
little is known about the mechanisms in which miRNAs are generated in plasma and the 
biological impact of these molecules in distant sites of the body. Studies suggest that 
RNA molecules associated to specific types of exosomes can be released in the 
circulating compartment on fusion of multivesicular bodies (MVB) with the plasma 
membrane and may be internalized by recipient cells by endocytosis (Figure 2.5) 
Literature review    18 
 
(Lotvall and Valadi 2007, Valadi et al. 2007). In addition, studies demonstrated the 
possibility to analyze miRNA expression using serum and plasma directly without any 
RNA extraction or serum filtration procedure (Chen et al. 2008). Therefore, lysed cells 
might contribute to the composition of miRNAs in the plasma. Nonetheless, additional 
studies are necessary to elucidate the mechanism in which miRNAs reach the 
bloodstream and the physiological impact of exosomal miRNA in global cellular 
processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Biogenesis of exosomes; A: At the limiting membrane of MVBs, several 
mechanism act jointly to allow specific sorting of transmembrane, chaperones, 
membrane associated and cytosolic proteins on the forming ILVs. B: Presence of 
several sorting mechanisms may induce heterogeneity in the population of ILVs in 
single MVBs by acting separately on different domains of the limiting membrane. C: 
Receiving lipids and proteins from the endocytic and the biosynthetic pathway, different 
subpopulations of MVBs may be generated whose composition confers them different 
fate: (1) back fusion of the ILVs with the limiting membrane. During this process 
molecules previously sequestered on the ILVs are recycled to the limiting membrane 
and to the cytosol. Change in the composition of the limiting membrane may be 
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responsible for the tubulation allowing plasma membrane expression of endosomal 
proteins. (2) Unknown mechanism may lead MVBs toward the plasma membrane 
where proteins such as SNAREs and synaptogamins would allow their fusion and the 
consequent release of the ILVs in the extracellular medium as exosomes. (3) Similarly, 
the composition of the limiting membrane would preferentially induce fusion of MVBs 
with lysosomes leading to the degradation of the molecules sorted on ILVs (van Niel et 
al. 2006). 
 
Although the presence of miRNAs in exosomes could explain their stability in serum, 
other possibilities include protection by chemical modifications or association with 
protein complexes. Nevertheless, there is a lack of an established endogenous miRNA 
control to normalize for plasma or serum miRNA levels measured by commonly used 
techniques as qRT-PCR. Usually, qRT-PCR data are normalized to an endogenous 
control gene, which is ideally stably expressed across the analyzed samples to reduce 
measurement errors, which may be due to technical variations (Davoren et al. 2008, 
Peltier and Latham 2008).  
 
To date, there are very few reports of validated controls that are used to normalize 
miRNA levels measured in serum or plasma. U6 small nuclear RNA (RNU6B), a 
control commonly used to normalize miRNA qRT-PCR data (Corney et al. 2007, Shell 
et al. 2007) was found to be less stably expressed than miR-93, miR-106a, miR-17 – 5p, 
and miR-25 in serum (Peltier and Latham 2008). Moreover, another study reported that 
RNAU6B and 5S ribosomal RNA were degraded in serum samples (Chen et al. 2008). 
In another study to identify stable controls for normalization, (Resnick et al. 2009) 
identified 2 of 21 miRNAs (miR-142-3p and miR-16) from a previous expression 
profile study with cycle threshold (Ct) differences of four cycles or greater between 
ovarian cancer patients and healthy controls. In another study, a robust normalization 
protocol was identified by using synthetic versions of Caenorhabditis elegans miRNAs 
(Mitchell et al. 2008).  
 
The exact process of how HDL is loaded with miRNAs and what proteins if any 
facilitate this association are not known. However, small RNAs (25 nucleotides) have 
previously been shown to complex with zwitterionic liposomes, specifically 
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phosphatidylcholine (Lu and Rhodes 2002). Previous biophysical studies indicate that 
HDL could simply bind to extracellular plasma miRNAs through divalent cation 
bridging. Interactions between DNA molecules and zwitterionic phosphatidylcholines 
resulted in conformational shifts in phosphatidyl- choline head groups and subsequent 
altered orientations of aliphatic chains, thus facilitating the incorporation of the DNA 
molecules into the protected space (Gromelski and Brezesinski 2006). In the case of 
HDL, this could lead to a tighter association with miRNAs, and could possibly shield 
bound miRNAs from external RNases (Mitchell et al. 2008).   
 
 
2.7 Hormonal regulation of microRNA biogenesis 
Steroid hormones are known to regulate target genes at both transcriptional and 
posttranscriptional levels when bound to specific nuclear receptors. MicroRNA 
biogenesis involves a nuclear processing event catalyzed by the microprocessor 
complex, which generates a short stem-loop structure known as a pre-miRNA from the 
primary miRNA (pri-miRNA) transcript. The core microprocessor complex consists of 
Drosha, an RNase III enzyme, and the DiGeorge syndrome critical region gene 8 
protein (DGCR8). In addition, other proteins can associate with the microprocessor, 
including the DEAD box helicases p68 and p72 and a number of hnRNP proteins 
(Gregory et al. 2004). Biogenesis of some miRNAs is regulated at the level of 
microprocessor and/or Dicer processing, as shown by the identification of RNA-binding 
proteins such as Lin28, hnRNP A1, and KSRP that can regulate the production of 
specific pre- and mature miRNAs (Heo et al. 2008; Macias et al. 2009; Michlewski et 
al. 2008; Trabucchi et al. 2009). However knowledge, about the signaling cascades that 
regulate miRNA biogenesis is little, but interesting details are beginning to emerge as 
findings have demonstrated that the transforming growth factor beta (TGF-b) and bone 
morphogenetic protein (BMP) signalling pathways positively regulate the Drosha-
mediated processing of miR-21, resulting in an induction of a contractile phenotype in 
human vascular smooth muscle cells (Davis et al. 2008). Pervious report of Kato 
laboratory has shown that the microprocessor-associated RNA helicases p68 and p72 
are required for the processing of a subset of miRNAs (Fukuda et al. 2007).  
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Progesterone control of miRNA production appears to be essential for normal 
development of numerous tissues, including the female reproductive tract. Conditional 
inactivation of Dicer in the Müllerian duct resulted in infertile female mice with small 
oviducts and uterine horns (Cochrane et al. 2012; Gonzalez and Behringer 2009). The 
increase in Dicer and Exportin-5 coincides with an increase in uterine expression of 
miR-451 (Nothnick et al. 2010). Dicer1 is higher in severe versus mild endometriosis 
(Aghajanova and Giudice 2011; Cochrane et al. 2012), whereas Dicer is found to be 
decreased in aggressive breast cancers (Cochrane et al. 2010; Grelier et al. 2009) and 
ovarian cancers (Faggad et al. 2010; Pampalakis et al. 2009). Alterations of components 
of the miRNA biogenesis pathway by P4, suggests that P4 treatment could have a global 
impact on miRNA expression. Progesterone control of miRNA production miRNAs 
appear to be essential for normal development of numerous tissues, including the female 
reproductive tract.  
 
In the other hand, the Kato lab described a specific example of how estrogens can 
indeed affect a posttranscriptional event by negatively regulating miRNA production 
(Yamagata et al. 2009). miRNA profiling result showed up regulation of a small subset 
of miRNAs in female mice deficient in estrogen receptor a (ERa). Conversely, estradiol 
(E2) treatment of ovariectomized female mice showed downregulation of some 
miRNAs in the uterus, an estrogen target organ. Altogether, this strongly suggests that 
ERa bound to E2 inhibits the production of a subset of miRNAs. The previous 
observation that ER a interacts with p68 and p72 raised the question how estrogen 
signals to the miRNA processing machinery (Watanabe. et al. 2001).  Interestingly, 
Yamagata and colleagues have found the interactory  E2-bound ERa with Drosha, 
which requires the presence of p68/72.  The increased level of VEGF transcription and 
mRNA stability have been affected by estrogen (Ruohola et al. 1999), and its 3´UTR 
harbors binding sites for estrogen-regulated miRNAs, such as miR-125a and miR-195. 
Therefore, VEGF regulation by these miRNAs provides a useful system to study the 
physiological relevance of E2-mediated miRNA regulation. Using luciferase reporters 
fused to the VEGF 3´UTR, Yamagata et al. showed that E2 treatment of MCF-7 cells 
caused elevated levels of the VEGF reporter, and this upregulation was mediated by the 
E2-mediated reduction in the levels of the corresponding miRNAs. This mechanism 
could be generally applicable to other E2/ERa target genes whereby the mRNA stability 
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of target genes is increased via inhibition of the processing of miRNAs that 
downregulate them (Figure 2.6). 
 
 
 
Figure 2.6  Estrogen Receptor-Mediated Inhibition of miRNA processing in the 
presence of estradiol (E2), ERa blocks Drosha processing of a subset of p68/p72-
dependent miRNAs (Macias et al. 2009). 
2.8 MicroRNA and follicular development  
For folliculogenesis and subsequent successful ovulation, a coordinated and 
bidirectional communications mediated by a large number of gene products is required 
(Albertini and Barrett 2003, Assou et al. 2006).  The expression of these genes must be 
precise and timely and any alteration in the expression of these genes could lead to 
oocyte developmental abnormalities, apoptosis, and poor cellular communication with 
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the supporting somatic cells affecting normal follicle recruitment and development 
(Toloubeydokhti et al. 2008). 
  
To demonstrate the importance of miRNAs in folliculogenesis, studies uncovered an 
essential function for Dicer, in regulating mouse oogenesis (Murchison et al. 2007, 
Tang et al. 2007). Disruption of Dicer specifically in growing oocytes resulted in their 
inability to complete meiosis, with defects in meiotic spindle organization and 
chromosome congression (Murchison et al. 2007). In wild-type mice, most Dicer 
expression was discovered  in fully grown germinal vesicle  (GV) oocytes, a time when 
their development is largely driven by regulated use of maternally stored mRNAs 
(Murchison et al. 2007, Schier 2007, Tang et al. 2007). The down regulation of Dicer, 
which is initiated with the onset of oocyte maturation, is common to many maternal 
mRNAs (Murchison et al. 2007, Schier 2007, Tang et al. 2007). These observations 
further point out the importance of Dicer in meiotic maturation of oocytes. During the 
course of meiotic maturation, the oocyte is transcriptionally quiescent, which persists 
through fertilization and pronucleus formation until the embryonic genome becomes 
active (Murchison et al. 2007, Schier 2007, Tang et al. 2007). More miRNAs are 
discovered in oocytes throughout the development and are considered to function as key 
regulators of maternally derived transcripts (Amanai et al. 2006, Murchison et al. 2007, 
Tang et al. 2007, Watanabe et al. 2006). Scientific data supporting the regulatory role of 
miRNAs in oocytes comes from two studies they show  direct evidence for the role of 
Dicer and requirement for miRNA processing in mature oocytes and the zygotes 
(Murchison et al. 2007, Tang et al. 2007), The biological implication of these miRNAs 
in human oogenesis is speculative, nevertheless nearly all the miRNAs identified are 
conserved in closely related species, or many have homologs in distant species, 
implying that their functions are conserved throughout the evolution (Bartel 2004, Farh 
et al. 2005). As such, it is possible that identical or similar maternally derived miRNAs 
also participate in regulation of oocyte and maternal-to-zygotic transcripts in humans. 
Whether alteration in maternally derived miRNA results in oocyte developmental 
failure in humans as seen in conditionally altered Dicer gene in mice, is unknown. 
However, transcriptional profiling of oocytes from polycystic ovary syndrome and from 
women with normal ovarian function (Liu et al. 2001, Luque-Ramirez et al. 2006, Park 
et al. 2007, Rajkovic 2007) implies a potential association between the level of 
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expression of these transcripts and regulatory function of miRNAs. Currently, the 
regulatory function of miRNAs in gene expression stability of granulosa and theca cells 
under physiologic and disease states remains to be elucidated. 
2.9 MicroRNA in the peri-implantation period 
The oviduct and the fluid contained in it provide a beneficial environment for gamete 
maturation, gamete transportation, fertilization and early embryonic development. 
These events are key processes in mammalian reproduction which are under the control 
of steroids (Murray et al. 1995) and prostaglandins (Lim et al. 1997). One possibility is 
that superstimulation accelerates embryo transport rate, resulting in their premature 
entry into the uterus, an environment in which O2 availability is limited (Hawk 1988). 
Studies in mice, bovine and humans have shown that superstimulation can lead to 
improper genomic imprinting and decreased embryo quality (Fauque et al. 2007, Gad et 
al. 2011, Rossignol et al. 2006, Sato et al. 2007), suggesting that ovarian hormonal 
stimulation may affect embryo development and gene expression in many different 
ways. In addition, an increase in chromosomal abnormalities has been reported in 
human embryos after conventional stimulation, mainly due to an increased incidence of 
chromosome segregation errors during the first embryonic divisions which was lowest 
in embryos divided in the expected time frame (Baart et al. 2009). 
 
During the oestrus cycle, inflammation-like processes occur aiming to prepare the 
immunological receptivity of the endometrium for implantation. These processes are 
controlled by several proteins, enzymes and angiogenic factors which are differentially 
expressed and tightly regulated (Morales Prieto and Markert 2011). Altered endometrial 
expression of these molecules seems to be responsible for inappropriate tissue 
regeneration, resulting in dysfunctional uterine bleeding, failed embryo implantation, 
and other endometrial disorders. Current reports have demonstrated that miRNAs 
participate in regulating dynamic changes in uterine gene expression patterns by 
controlling genes associated with the inflammatory response (Chakrabarty et al. 2007, 
Pan and Chegini 2008). A number of miRNAs are specifically expressed during the 
peri-implantation and pre-implantation periods in mice. Among the 32 miRNAs 
identified as up regulated during the receptive phase, miR-101 and miR-199a* were 
shown to target the cyclooxygenase-2 (Cox2) gene, which is known for its critical role 
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in implantation and for its abilities to promote inflammation and tumorigenesis 
(Chakrabarty et al. 2007, Morales Prieto and Markert 2011). 
 
The significant rise in expression profiles obtained for mature miR-21 and miR-130a 
from one to eight cell stage embryo; they unexpected patterns could indicate an activity 
of miRNAs on mRNAs carrying a seed sequence in their 3′UTR during the first 
segmentations of the embryo (Mondou et al. 2012). In another study, the quantification 
of miR-10 and miR-424 in early bovine development showed a steady expression level 
from the GV oocyte until the 16-cell embryo (Tripurani et al. 2010). Other profile 
results were presented for miR-125, miR-127 and miR-145, which showed an increased 
expression level by the 4- and 8-cell embryo (Tesfaye et al. 2009). Moreover, miR-196a 
increases steadily from the 2- to the 8-cell embryo (Tripurani et al. 2011).All these 
results could propose an implication for these specific miRNAs during the maternal-to-
embryonic transition (MET). Additionally, this previous study showed the potential 
evidence of a direct negative regulation of a maternal transcript, the NOBOX element, 
by miR-196a. The first report that some miRNA could originated from de novo 
transcription during the bovine pre-MET phase (Mondou et al. 2012).  
 
In all these cases, a decreased expression level of these miRNAs was observed at the 
blastocyst stage and emphasized the expression period of the mature miRNAs during or 
before the MET(Mondou et al. 2012). Those profiles were interesting because the 
expression level increased from the 1- to 8-cell embryo stage instead of decreasing like 
total mRNA profiles (Mondou et al. 2012). As mentioned earlier for the trout and the 
zebrafish, these specific augmentations of certain miRNAs during the MET suggest a 
putative role in the destruction of the maternal target mRNAs at the MET (Giraldez et 
al. 2006, Ramachandra et al. 2008). The calculated ratios of mature-to-precursor forms 
can additionally illustrate this particular expression pattern at the MET, especially with 
miR-130a where the mature form decreased to an equal concentration to the precursor 
form at the blastocyst stage. Consequently, this marked decrease of the mature form at 
the blastocyst stage suggests a role for the miRNA during the MET. With these 
differential values obtained between the mature and the precursor forms, a recent study 
illustrates the importance of quantifying the corresponding precursor stem-loop 
sequence (Mondou et al. 2012). 
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Development of transvaginal endoscopy in cattle has allowed unrivalled access to the 
bovine oviduct for the recovery or transfer of embryos at different developmental 
stages, and offers an excellent tool for studying the early kinetics of embryo 
development as well as the effects of hormonal stimulation on embryo physiology 
(Besenfelder et al. 2001, Besenfelder et al. 2008). As a result of progress in 
optimization of this nonsurgical endoscopic access to the oviduct, there has been a 
steady increase in pregnancy rate after transfer of early cleavage stage embryos to the 
oviduct (Besenfelder et al. 2010, Gad et al. 2011). To our knowledge, the changes in the 
oviduct and uterine environment due to hormonal treatments and subsequent influence 
on transcriptome profile of embryos have not been investigated. It is well known that 
superstimulation leads to deviant oocyte maturation in the follicle (Hyttel et al. 1989) as 
well as an abnormal endocrine environment in the reproductive tract. Therefore this 
study aimed to separate these two processes and examine the effect of an abnormal 
endocrine environment on embryo development to Day 7 and its influence on the 
blastocyst transcriptome. To do this, a state-of-the-art nonsurgical endoscopy method 
was used to recover 2- to 4-cell stage embryos from superstimulated donors and to 
transfer them to non-stimulated single-ovulating recipients. The proportion of embryos 
developed to the blastocyst stage and the transcriptome of the resulting blastocysts was 
compared. These data have relevance not only for cattle embryo production but also for 
assisted human reproduction where oocytes derived from women undergoing ovarian 
stimulation are routinely replaced in the uterus of the same women during the same 
cycle, in contrast to the situation in cattle, where transfer to unstimulated surrogate 
recipients is the norm. This is highlighted by the fact that high-quality embryos 
transferred into women involved as embryo recipients in a surrogacy procedure have a 
higher likelihood of implanting than if they are transferred back into the donors (Check 
et al. 1992, Stafford-Bell and Copeland 2001) . 
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3  Materials and methods  
 
3.1 Materials for laboratory analysis  
In this section, materials used in this study such as chemicals, kits, all other biological 
materials, reagents, media, equipments, softwares and their sources are mentioned. 
3.1.1 Chemicals, kits, biological and other materials 
 
Chemicals, kits, biological and other materials Manufacturer/Supplier 
10x PCR buffer                                       Promega, WI, USA 
2x SYBR Green master mix, Universal RT Exiqon, Vedbaek, Denmark 
2-Mercaptoethanol Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
5x First-Strand buffer Invitrogen Life Technologies, 
Karlsruhe, Germany 
Acetic acid Roth, Karlsruhe, Germany 
Agarose                                                         Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Ammonium acetate Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
BME (essential amino acids) Gibco BRL, life technologies, 
Karlsruhe, Germany 
Bovine serum ablbumin (BSA) Promega, Mannheim, Germany 
Brilliant cresyl blue stain (BCB) Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Calcium chloride dihydrate Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Chloroform Roth , Karlsruhe, Germany 
Materials and methods  28 
 
Citric acid Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Diethylpyrocarbonate (DEPC)  Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Roth , Karlsruhe, Germany 
dNTPs Roth , Karlsruhe, Germany 
Dithiothreitol (DTT) 
Invitrogen Life Technologies, 
Karlsruhe, Germany 
Ethanol Roth, Karlsruhe, Germany 
Ethidium bromide Roth, Karlsruhe, Germany 
Ethylenediaminetetra acetic acid (EDTA) Roth , Karlsruhe, Germany 
ExoSAP-IT USB, Ohio, USA 
Fetal bovine serum (FBS) Gibco, Karlsruhe, Germany 
Gentamycin sulphate Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Hemi-calcium lactate Promega, WI, USA 
HEPES Sigma-Aldrich Chemie GmbH, 
Munich,Germany 
Hyaluronidase Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Hydrochloric acid Roth, Karlsruhe, Germany 
Hydroxylamine Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Igepal Roth, Karlsruhe, Germany 
Ionomycin Sigma-Aldrich, Chemie GmbH, 
Munich, Germany 
Isopropyl -D-thiogalactoside (IPTG) Roth, Karlsruhe, Germany 
L-Glutamine Sigma-Aldrich, Germany 
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Magnesium chloride Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Medium 199 Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Methanol Roth, Karlsruhe, Germany 
MicroRNA LNATM PCR primer set Exiqon, Vedbaek, Denmark 
MicroRNA Ready-to-Use PCR Panels Exiqon, Vedbaek, Denmark 
Mineral oil 
Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
MiRNA PCR array Exiqon, Vedbaek, Denmark 
MiRNeasy® mini kit QIAGEN, Hilden, Germany 
Nuclease free water Exiqon, Vedbaek, Denmark 
Oligonucleotide primers MWG Biotech, Eberberg, Germany 
Oligo (dT) 23 Promega, WI, USA 
Penicillin G Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Peptone Roth, Karlsruhe, Germany 
Phenol red solution (5% in D-PBS) Sigma-Aldrich Chemie GmbH , 
Munich, Germany 
PKH67 Green Fluorescent Cell Linker mini kit Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Potassium chloride 
Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Proteinase K Roth, Karlsruhe, Germany 
QIAquick PCR Purification Kit QIAGEN, Hilden, Germany 
Random primer Promega, WI, USA 
Ribo-nuclease inhibitor (RNasin) Promega, WI, USA 
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RNA later Sigma-Aldrich, MI, USA 
Ribo-nuclease inhibitor (Rnasin) Promega, WI, USA 
RNA 6000 Nano LabChip® kit Agilent Technologies Inc, CA, USA 
Roti PAGE gradient (4-20%) 
Carl Roth GmbH, Karlsruhe, 
Germany 
Rotiphorese Gel 30 (37, 5:1) 
Carl Roth GmbH, Karlsruhe, 
Germany 
RQ1 Rnase-free Dnase Promega, WI, USA 
Sample Loading Solution (SLS) Beckman Coulter, Krefeld, 
Germany 
Sodium acetate Roth , Karlsruhe, Germany 
Sodium bicarbonate Sigma-Aldrich chemie, Steinheim, 
Germany 
Sodium chloride Roth , Karlsruhe, Germany 
Sodium citrate Roth, Karlsruhe, Germany 
Sodium hydrogen carbonate Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Sodium dihydrogen phosphate Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Sodium hydrogen sulphate Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Sodium pyruvate Sigma-Aldrich Inc, MO, USA 
Streptomycin Sigma-Aldrich, Deisenhofen, 
Germany 
Streptomycin sulphate Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
Superscript II reverse transcriptase Invitrogen,  CA, USA 
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SuperSignal West Pico Chemiluminescent Substrate Thermo Scientific, Rockford, 
U.S.A. 
Taq DNA polymerase Sigma-Aldrich Inc, MO, USA 
TCM-199 Sigma-Aldrich Chemie GmbH, 
Munich, Germany 
TEMED Roth, Karlsruhe, Germany 
Tris Roth, Karlsruhe, Germany 
Trypsin-EDTA Sigma-Aldrich, Chemie GmbH, 
Munich, Germany 
Tween-20 Roth, Karlsruhe, Germany 
Universal cDNA synthesis kit  Exiqon, Vedbaek, Denmark 
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3.1.2 Reagents and media preparation 
During this experiment, the following reagents and media formulation were used. All 
solutions used in this study were prepared with deionised and demineralised millipore 
water (ddH2O) and when necessary, the pH was adjusted with sodium hydroxide 
(NaOH) or hydrochloric acid (HCl). In addition, the solutions or buffers were 
subsequently filtered through 0.2 µ filter and autoclaved at 120°C for 20 minutes when 
it is necessary. 
 
 
Name of the buffer/media Constituents  Volume / 
amount 
Physiological saline solution NaCl 9.0 g 
( NaCl 0.9%) ddH2O added to 1000.0 ml 
   
Manipulation medium TCM-199  1500.0 g 
 Gentamycine sulfate  0.050 g 
 Sodium pyruvate  0.022 g 
 NaHCO3  0.350 g 
 BSA  
 
1.00 g 
                                                                                                                               
70% Ethanol Ethanol (100%) 700 ml 
 ddH2O added to 300 ml 
   
10x CMF (Calcium manesium free  Sodium chloride (NaCl) 8 gm 
PBS) Potasium chloride (KCl) 0.2 gm 
 Sodium hydrogen phosphate 
(Na2HPO4) 
1.15 
 Potasium hydrogen phosphate 
(KH2PO4) 
0.2 gm 
 ddH2O added to 1000 ml 
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10x PBS NaCl  8.77 g 
 Na2HPO4  1.50 g 
 NaH2PO4  2.04 g 
 ddH2O added to 1000.0 ml 
   
1x PBS 10x PBS  100 ml 
 DEPC-treated water upto 1000 ml 
   
3% BSA in PBS BSA 30g 
 10x PBS : added to 1,000.0 ml 
   
3M Sodium acetate, pH 5.2 Sodium acetate  123.1 g 
 ddH2O added to 500 ml 
 
   
Agarose loading buffer Bromophenol blue 0.0625 g 
 Xylencyanol 0.0625 g 
 Glycerol 7.5 ml 
 ddH2O added to 25 ml 
   
DEPC-treated water (1000 ml) DEPC 1 ml 
 ddH2O added to 1000 ml 
   
dNTP solution dATP (100 mM) 10 µl 
 dGTP (100 mM) 10 µl 
 dTTP (100 mM) 10 µl 
 ddH2O added to 400 µl 
   
EDTA 100 Mm (pH 2.0)  EDTA 37.224 g 
 Water up to  1000.0 ml 
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4 % paraformaldehyde  Paraformaldehyde  4.0 g 
 1X PBS 100.0 ml 
   
Guanidin-Ethanol solution (50 ml) Guanidin 1.43 gm 
 95% Ethanol up to 50 ml 
   
Proteinase K solution  Proteinase K 20 mg 
 DEPC-treated H2O 1 ml 
   
   
Lysis buffer Igepal (0.8%)  0.8 µl 
 40U RNasin  5.0 µl 
 DTT  5.0 µl 
 ddH2O added to 100.0 µl 
   
Resolving solution Rotiphorese gel 2 ml 
 Trenngel buffer  1.25 ml 
 ddH2O added to 1.65 ml 
 APS (10%) 25 µl 
 TEMED 5 µl 
   
1x Blotting Buffer (500 ml) 10x blotting buffer 50 ml 
 Methanol 100 ml 
 ddH2O added to 350 ml 
   
Fixation solution Methanol 500 ml 
 Glacial acetic acid 100 ml 
 ddH2O added to 1000 ml 
   
Coomassie staining solution Coomassie Blue R-250 2 ml 
 Methanol 500 ml 
 Glacial acetic acid 100 ml 
 ddH2O added to 1000 ml 
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Stacking Solution Rotephorese gel 0.725 ml 
 Sammel gel buffer 0.5 ml 
 ddH2O added to 2.825 ml 
 APS (10%) 20 µl 
 TEMED 5 µl 
   
Stripping solution Glycin 15 gm 
 SDS 1 gm 
 Tween 20 10 ml 
 ddH2O added to 1000 ml 
   
Urea-DTT solution Urea 3 gm 
 ddH2O added to 3 ml 
 Stock DTT 250 µl 
 
3.1.3 Equipments used in the study  
 
Equipment Manufacturer 
ABI StepOnePlus™ Applied Bio Systems, CA, U.S.A. 
ABI 7900 HT real time PCR system Applied Bio Systems, CA, U.S.A. 
Agilent 2100 Bioanalyzer Agilent Technologies , CA, USA 
ApoTome microscope  Carl Zeiss Microlmaging, Germany 
Centrifuge Hermel, Wehingen, Germany 
CEQTM 8000 Genetic Analysis Beckman Coulter, Krefeld, Germany 
Confocal laser scanning microscope-510 Carl Zeiss, Germany 
CO2-incubator (MCO-17AI) Sanyo, Japan 
ECL plus western blotting detection system GE Healthcare, Freiburg, Germany 
Eight well chamber slide Lab-TekTM, Thermo Scientific, US 
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Electrofusion machine CFA 400 Kruess Hamburg, Germany 
Electrophoresis unit BioRad, Munich, Germany 
Four well culture dishes Thermo Fisher Scientific, Nunc, 
Denmark 
Inverted fluorescence microscope DM IRB Leica, Germany 
Nanodrop 8000 spectrophotometer  Thermo Fisher Scientific, DE, USA 
Millipore apparatus Millipore Corporation, USA 
MyCycler Thermal Cycler  Bio-Rad Laboratories, CA, USA 
MicroAmp® optical 96-well reaction plate 
with barcode  
 
Applied Bio Systems 
Stereomicroscope SMZ 645 Nikon, Japan 
StepOnePlus real-time PCR system Applied Bio Systems 
Tweenty four well culture dishes Thermo Fisher Scientific, Nunc, 
Denmark 
Ultra centrifugation machine Beckman Coulter, Krefeld, Germany 
Ultra-low freezer (-80oC) Labotect GmbH, Göttingen, Germany 
UV Transilluminator (Uvi-tec)  Uni Equip, Martinsried, Germany 
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3.1.4  List of software programs and statistical packages used   
Programs (soft wares) and statistical 
packages 
Source  
BLAST program  http://www.ncbi.nlm.nih.gov/Blast/ 
EndNote X1 Thomoson 
ENSEMBL genome browser  http://www.ensembl.org/ 
Entrez Gene http://www.ncbi.nlm.nih.gov/ 
GraphPad prism v.5  GraphPad software, Inc. 
Ingenuity's pathway analysis  www.ingenuity.com 
MiRBase v.19 http://www.mibase.org/ 
miRDB  http://www.mirdb.org/ 
MicroRNA.org-Target and Expression http://www.microrna.org/ 
miRecords http://mirecords.biolead.org/ 
PicTar  http://www.pictar.org/ 
Primer Express® software v.2.0 Applied Biosystems, Foster City, CA, 
USA 
RT2 PCR Array Data Analysis Version 3.5 http://pcrdataanalysis.sabiosciences.co
m/ 
Primer 3 (version 4) http://frodo.wi.mit.edu/primer3/ 
Prism for windows (ver.5.0) GraphPad software, Inc. 
TargetScan 5.1 http://www.targetscan.org/ 
Weight to molar quantity (for nucleic acids) 
converter 
http://www.molbiol.ru/eng/scripts/01_0
7.html 
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3.2  Methods 
3.2.1 Experimental design 
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Figure 3.1 Overview of the present study : All experimental animals were handled 
according to the animal protection law of Germany. Simmental heifers (n =12) aged 
between 15 and 17 months and weighing between 380 and 450 kg is used in this study. 
All animals were kept under identical farm conditions within the same herd.  Blood 
samples for miRNA detection were collected by EDTA tubes from the both group 
animals on day zero, day three and day 7 after ovulation and stored at -80ºC. In 
addition, Follicular fluid were collected from the both group animals on day zero was 
stored at -80ºC.Total RNA from blood plasma and follicular fluid were isolated by 
using the miRNeasy kit (Qiagen, Hilden, Germany).  Reverse transcription will be 
performed by using universal cDNA syntheses Kit (Exiqon, Vedbeck, Denmark) 
according to the manufacture's protocol. Identification and expression profiling of 
miRNA were performed by PCR based array technology. We used miRCURY LNA™ 
Ready-to-Use PCR.Samples were profiled for candidate miRNAs by using miRNA RT-
PCR individual assay.  
 
3.2.2 Animal treatments and sample collection  
 
All experimental animals were handled according to the animal protection law of 
Germany. Simmental heifers (n =12) aged between 15 and 17 months and weighing 
between 380 and 450 kg were used in this study. All animals were kept under identical 
farm conditions within the same herd. Pre-synchronization was performed by i.m. 
administration of 500 mg of cloprostenol (PGF2a, Estrumatew; Essex Tierarznei, 
Munich, Germany) twice within 11 days. Two days after each of the PGF2a treatments 
animals received 10 mg of GnRH (Receptalw; Intervet, Boxmeer, the Netherlands). 
Twelve days after the last GnRH injection, heifers received the first of eight consecutive 
FSH-injections over 4 days in decreasing doses (in total 300–400 mg of FSH equivalent 
according to the body weight; Stimufol, University of Liege, Belgium). Two PGF2a 
treatments were performed 60 and 72 h after the initial FSH injection. Finally, 48 h after 
the first PGF2a application, ovulation was induced by simultaneous administration of 10 
mg of GnRH with the first of three artificial inseminations within a 12-h interval. The 
time of the second insemination (60 h after the first PGF2a application) was defined as 
Day onset of oestrus (D0)(Figure 3.2). The estrous cycles of recipient animals were 
Materials and methods  40 
 
synchronized as mentioned above, but were not inseminated. Follicular contents 
(follicle ≥35 mm) were collected by transvaginal, ultrasound-guided follicular 
aspirations(figure . Follicular fluid was collected using a 12-gauge needle, centrifuged 
at 1500xg for 15 min, and later stored at -80°C and also  blood samples were collected 
from each animal from D0, day 3 (D3) and day7 (D7) by tail venipuncture. Blood 
plasma for miRNA detection was collected by EDTA tubes from the both group animals 
and stored at -80ºC until processed for microvesicles/ exosomes, RNA, or protein 
isolation. Blood samples were refrigerated at 4°C for 12–24 h before being centrifuged 
at 1500g at 4°C for 15 min. Serum was separated and stored at -20°C until assayed to 
determine progesterone concentration.  
 
 
 
 
Figure 3.2 Overview of the ovarian hyperstimulation protocol 
  
3.2.3 Progesterone assay  
 
Progesterone concentrations were measured with commercially available assay kits. In 
hyperstimulated (n=6) and unstimulated heifers (n=6) at day 0 to day7 of oestrous. 
Progesterone concentration was determined by time-resolved fluoroimmunoassay using 
 
11 days 
PGF2α 
GnRH 
PGF2α 
GnRH 
2 
da
ys 
2 
da
ys 12 days 
n=6 
FSH (8x) 
4 days 
PGF2α 
60 h 72 h 
Synchronized animals n=6 
4 days 
Materials and methods  41 
 
an Auto DELFIA ™ Progesterone kit (Perkin Elmer, Wallac Oy, Turku, Finland). The 
sensitivity of the assay was 0.01ng/ml. 
 
3.2.4 Total RNA isolation 
 
 
The total RNA enriched with miRNAs was isolated from the experimental samples 
using miRNeasy® Mini kit (QIAGEN, Hilden, Germany) according to manufacturer's 
instructions with the following modifications. Liquid samples (follicular fluid and blood 
plasma), ultracentrifugation pellets and immunoprecipitation pellets were resuspended 
in 800 µL of QIAzol (Qiagen, Hilden, Germany) by vortexing for 1 min then incubated 
at room temperature for 5 min. Two hundreds µL  chloroform was added to the 
homogenate, the tube shacked vigorously for 15 sec and incubated at room temperature 
for 2 min and centrifuged for 15 min at 12000 x g at 4°C in refrigerated universal 
centrifuge Z233MK (Hermle Labortechnik, Wehingen, Germany). The upper aqueous 
phase was transferred carefully to a new 2 ml collection tube and 1.5 volume of 100% 
ethanol was added. After mixing, 700 µl of the sample was pipetted onto RNeasy Mini 
spin column and centrifuged for 15 sec at room temperature. The flow-through was 
discarded and the previous step was repeated with the remaining samples. Following 
this, the spin column was washed by 700 µl RWT buffer and centrifuged for 15 sec at 
10000 rpm. After discarding the flow-through, 500 µl RPE buffer was added to the spin 
column followed by 15 sec centrifugation of 10000 rpm. This step was repeated for the 
second time and centrifuged at the same speed for 2 min. The spin column was then 
transferred to a new 2 ml collection tube and centrifuged at 14000 rpm for 1 min to 
eliminate any possible carryover of RPE buffer and residual flowthrough remained on 
the spin column. To elute total RNA, the RNeasy spin column was transferred into new 
1.7 ml collection tube to which 30 µl of RNase-free water was added to the centre of the 
RNeasy spin column membrane and centrifuged at a speed of 10000 rpm for 1 min. 
Isolated total RNA was stored in -80°C until the further step. 
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3.2.5 Reverse transcription 
 
A reverse transcription reaction was performed using the miRCURY LNA™ Universal 
RT microRNA PCR system (Exiqon, Denmark) according to the manufacturer’s 
instructions. In brief, approximately a total of 100 ng of total RNA, including small 
RNA, were anchor-tailed with a poly(A) sequence at their 3'end and then reverse 
transcribed into cDNA using a universal poly(T) primer with a 3'end degenerate anchor 
and a 5' end universal tag. For this, 5x reaction buffer and nuclease free water was 
gently thawed and immediately placed on ice. RNA spike-in was resuspended by adding 
40 µl of nuclease free water and mixed by vortexing prior to use. The RT master mix 
was prepared by adding 5x reaction buffer, water, enzyme mix and spike-in RNA in the 
proportion indicated in the following table. The RT master mix was dispended into 
nuclease free tube and then the total RNA template was added to each tube and mixed 
by gentle vortexing or pipetting. The mix was incubated for 60 min at 42°C and 5 min at 
95°C. After the incubation period samples were immediately cooled by placing in ice. 
The cDNA products were subsequently diluted 100 fold. 
 
Table 3.1 Reverse transcription reaction setup 
Reagent Volume (µl), 
RT reaction 
5x Reaction buffer        4 
Nuclease-free water        9 
Enzyme mix        2 
Synthetic RNA spike ins, optional replace  
with H2O if omitted 
       1 
Template total RNA        4 
Total volume       20 
 
 
3.2.6 Quality control of isolated RNA 
 
For all the experiments, the resulting total RNAs were checked for their concentration 
and integrity (based on 260/280 nm measurement) using nanodrop 8000 
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spectrophotometer (Thermo Scientific, Germany) and subsequent analysis by using 
Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA). Therefore, an alternative 
way of monitoring yield and quality control of the sample has to be used. The amount of 
RNA that can be extracted as well as the amount of inhibitors left after extraction can 
vary from sample to sample. Before committing RNA samples to profiling on 
microRNA qPCR panels, it is very important to ascertaining the purification yield and 
absence of PCR inhibitors. So, for this we  perform real time PCR using different RNA 
sample input amounts in the cDNA synthesis reaction, for instance 0.5 µL, 1.0 µL, 2.0 
µL, and 4.0 µL in a 10 µL reaction. Corresponding cDNA samples were analysed by 
qRT-PCR using miR-16 and miR-191.  
 
3.2.7 miRNA Profiling 
 
Samples were profiled for the relative abundance of 750 miRNAs by using miRNA 
Ready-to-Use PCR, Human Panel I &II I, V2.M qRT-PCR arrays (Exiqon, Vedbaek, 
Denmark) in ABI Prism® 7900 HT SDS (Applied Biosystems, Foster City, CA). To 
empirically determine the limit of linear quantification, the limit of detection, and the 
PCR efficiency for each miRNA assay, we used dilution analysis of plasma circulating 
miRNA for reverse transcription with the miRCURY LNA Universal RT miRNA PCR 
kit (Exiqon, Vedbaek, Denmark). As directed reverse transcription reaction products 
were combined with SYBR Green master mix (Exiqon, Vedbaek, Denmark) and loaded 
into the 384-well qRT-PCR arrays as directed. Quantitative PCR was performed on a 
ABI Prism® 7900 HT (Applied Biosystems, Foster City, CA). Data from all miRNA 
qRT-PCR arrays were imported into SDS Enterprise Software (V2.2.2; Applied 
Biosystems), and CT values were calculated by using automated assay-specific baseline 
and threshold settings. Plasma and follicular fluid datasets were subsequently analyzed 
independently. MicroRNAs were first normalized using global mean normalization 
across all miRNA arrays to achieve the same mean Ct (determined using only miRNAs 
passing detection threshold (Ct<32) for each array). To minimize potential noise 
introduced by measurements below detection threshold, miRNAs with Ct>35 in all 
groups were filtered out. 
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3.2.8 Exosomes isolation  
 
Exosome isolation from independent follicular fluid samples was also performed by 
ultracentrifugation using previously described methods (Arroyo et al. 2010, Valadi et al. 
2007). Briefly, follicular fluids were subjected to differential centrifugation at 300xg 
and then 4000xg each for 10 min to remove cells and cellular debris. The follicular fluid 
samples were then filtered through 0.22 µm screen to remove particles whose size is 
more than 200 nm (apoptotic bubbles and microvesicles portion). After that, samples 
were subjected to centrifugation at the 25,000×g for 30 minutes to remove further 
microparticles, and the microvesicles fraction remained in samples after filtration. 
Follicular fluids, obtained from 25,000×g centrifugation steps, were centrifuged at 
120,000×g for 70 minutes at 4°C in a Beckman SWTi55 rotor. The resulting exosome 
pellet was resuspended in DPBS and re-centrifuged at 120,000×g for 70 min at 4°C and 
then resuspended in DPBS and stored until further use for exosome labeling and the  
uptake experiment. 
3.2.9 AGO 2 immunoprecipitation 
 
 A total of 200 µL of plasma was diluted with 200 µL of PBS solution (pH 7.4). For 
each sample, 200 µL of Magna Bind goat anti-mouse IgG Magnetic Bead slurry 
(Thermo Scientific, Rockford , USA ) were washed with PBS solution and incubated 
with 10 µg of mouse monoclonal anti- Ago2 mouse normal IgG (Santa Cruz   
Biotechnology, Heidelberg, Germany) antibodies for 2 h at 4 °C. The preincubated 
beads and antibody were then added to the 400 µL of diluted plasma and incubated 
overnight at 4 °C. Beads were washed three times with 1% Nonidet P-40 buffer (1% 
Nonidet P-40, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA.  Each sample 
was eluted in 700 µL of QIAzol and processed for RNA isolation.  
3.2.10 Protein isolation and Western blot analysis  
 
Exosomal proteins and the Ago2 complex were isolated from organic phenol portion 
during total RNA isolation using Qiagen miRNeasy mini kit following optimized 
protocol and resuspended in 8M urea.  Briefly, after complete removal of aqueous phase 
300 µl of 100% ethanol was added, mixed carefully and incubated at room temperature 
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for 2-3 min. Following centrifugation at 2000 × g at 4°C, supernatant containing the 
protein frection was transferred to a new cap lock tube, 1.5 ml of isopropanol added , 
and incubated for 10 min at room temperature. Samples were centrifuged at 12,000 × g 
for 10 min at 4°C, the supernatant was removed and 2 ml of guanidin-ethanol solution 
was added and incubated for 20 min followed by centrifugation at 7500 × g at room 
temperature. After removing the supernatant 2 ml of 100% ethanol was added, vortexed 
and incubated at room temperature for 20 min. Then 500 µl of urea-DTT solution was 
added and incubated at 95°C for 3 min. The solution containing protein was transferred 
into a new tube and centrifuged at 10,000 × g for 10 min. The supernatant containing 
protein was then transferred into new tube and the quantity was measured using 
nanodrop.  Fifty µg of protein from each sample were loaded and resolved in 12% SDS-
PAGE polyacrylamide gels (Bio-Rad, Corp., Hercules, CA, USA) and then  transferred 
to nitrocellulose membranes (Biotrace NT, Pall Life Sciences, Pensacola, FL, USA). 
Membranes blocked (5% non-fat dried milk in TBST) for 1 h at room temperature and 
incubated separately with antibodies raised against CD63 (ExoAB Antibody, SBI, CA, 
USA) and EIF2C2 (0.4 µg/ml; Santa Cruz Biotechnology Inc, USA) overnight at 4°C. 
After subsequent washing, membranes preincubated with the respective primary 
antibody were further incubated with horseradish peroxidase conjugated anti-goat, anti-
rabbit and anti-mouse secondary antibodies (Santa Cruz Biotechnology Inc., USA), 
respectively.  After additional washes, membranes were incubated for 5 min in 
chemiluminescent substrate (Thermo Scientific, Waltham, USA), and immunoreactive 
proteins were visualized with a Chemidoc XRS (Bio-Rad) instrument. 
 
3.2.11 Quantitative real time PCR analysis of selected microRNAs 
The expression profiling of selected miRNAs in granulosa cells, theca cells and oocyte 
cumulus complexs have been examined using LNATM PCR miRNA qPCR. Individual 
primer set was used. Complementary DNA was synthesized from total RNA of the 
exosomal portion, Ago 2 complex portion, blood plasma and follicular fluid  according 
to the previously mentioned protocol using Universal cDNA synthesis kit (Exiqon, 
Vedbaek, Denmark). The resulting cDNA was diluted 40x using nuclease free water. 
The qRT PCR master mix was prepared using the 4 µl of diluted cDNA template, 1µl 
LNATM PCR miRNA qPCR assay primer set and 5 µl of 2x SYBR Green master mix 
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(Exiqon, Vedbaek, Denmark). The reaction was done by using ABI prism 7000 real 
time PCR apparatus with a thermal program of initial heating at 95°C for 10 min 
followed by 40 cycles of 95°C for 10 sec and 60°C for 1 min. The relative 
quantification of miRNAs expression was calculated using a comparative threshold 
cycle (Ct) method as described before (Tesfaye et al. 2009). 
Where, relative abundance (Fold change) = 2-∆∆Ct  
∆Ct = average Ct target miRNA - average Ct of normalizer  
∆∆Ct = ∆Ct target miRNA - ∆Ct of the calibrator 
The calibrator was the one with the highest ∆Ct value among the groups 
 
3.2.12 Target prediction and pathway analysis  
 
Target Scan 6.2, PicTar and miRecords were used to predict target genes of the 
deregulated miRNAs identified.  A list of the target predicted genes was uploaded into 
the Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, 
www.ingenuity.com) to filter targeted genes and also to identify relationships between 
the genes of interest and to uncover common processes and pathways. Networks of the 
genes were then algorithmically generated based on their connectivity. The ‘Functional 
Analysis’ tool of the IPA software was used to identify the biological functions that 
were most significant to the data set. Canonical pathway analysis was also utilized to 
identify the pathways from the IPA library of canonical pathways that were most 
significant to the data set. Fisher’s exact test was used to calculate a p-value 
determining the probability that each biological function or canonical pathway assigned 
to the data set. In addition, the significance of the association between the data set and 
the canonical pathway was calculated as the ratio of the number of genes from the data 
set that mapped to the pathway divided by the total number of genes that mapped to the 
canonical pathway. 
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4 Results 
 
4.1 Effect of hyperstimulation on progesterone profile  
The progesterone profiles of blood serum from hyperstimulated and unstimulated 
heifers were shown in (Figure 1). The mean progesterone concentration at day 7 was 
19.59±8.1 and 2.11±1.10 ng/ml for the hyperstimulated and unstimulated heifers, 
respectively. 
 
Figure 4.1 Progesterone (P4) profile of hyperstimulated (n=6) and unstimulated heifers 
(n=6) at day 0 onset of oestrous to day7. The plasma P4 concentration (SD) is indicated 
as Mean ± SEM and *** designate significant a level with p<0.0001. 
 
 
 
4.2 Quality control of total RNA 
 
Reliable results in real-time RT-PCR array and microarray analysis depend on the 
quality of the RNA sample. Standard methods for measurement of the RNA yield and 
quality are inappropriate for use with biofluid samples. The presence of carrier RNA in 
these samples makes measuring the low levels of endogenous RNA by OD260 
impossible. Even if carrier was not included during the isolation, the RNA 
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concentration in the eluate would still be too low for reliable OD260 quantification on a 
NanoDrop or other spectrophotometers. Therefore, an extensive alternative quality 
control of total RNA has been implemented to secure technical soundness. For this total 
RNA from exosomes and non-exosomal fraction of follicular fluid was synthesized to 
cDNA with different inpute volume (i.e. 0.5 µl, 1 µl, 2 µl and 4 µl) and subsequently 
examined by quantitative real time PCR using miR-103 and miR-109. Following this, a 
correlation analysis was performed between the input volume of total RNA and 
threshold cycle value (Ct) of specific miRNA. The results revealed that miR-103 
generated a linear curve for the total RNA samples from follicular fluid and blood 
plasma  (Figure 4.2). On the other hand, the expression of miR-191 in exosome samples 
showed a linear pattern, for follicular fluid and blood plasma the deviation from 
linearity was acceptable (Figure 4.3). 
 
 
Figure 4.2 Expression of miR-103 in follicular fluid and blood plasma across the input 
volume (A) and amplification graph in qRT-PCR (B). Where Ct is the threshold cycle 
value and Rn is the fluorescence of the reporter dye divided by the fluorescence of a 
passive reference dye. (B) Amplification plot shows the variation of log (∆Rn) with 
PCR cycle number. 
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Figure 4.3 Expression of miR-191 in follicular fluid and blood plasma across the input 
volume (A) with amplification graph in qRT-PCR (B). Where Ct is the threshold cycle 
value and Rn is the fluorescence of the reporter dye divided by the fluorescence of a 
passive reference dye. (B) Amplification plot shows the variation of log (∆Rn) with 
PCR cycle number. 
 
 
4.3 Expression profile of circulating miRNA 
Real time PCR based miRNA arrays were used to measure the abundance of 742 
miRNAs in the follicular fluid and blood plasma at day 7 from a single animal. 
Identification of differentially expressed miRNAs at first, we made hyperstimulated 
group-versus-control group (unstimulated) comparisons (i.e., 4 vs. 4). This analysis 
revealed that both in follicular fluid and blood plasma contain a large array of miRNAs. 
Among the 748 miRNAs profiled, 510 and 407 miRNAs were detected in follicular 
fluid and blood plasma, respectively. From the detected miRNAs, a total of 377 
miRNAs were commonly detected in both follicular fluid and blood plasma. However, 
143 and 30 miRNAs were detected only in follicular fluid and blood plasma (Figure 
4.4). 
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Figure 4.4 Venn diagram showing the number of detected miRNAs in bovine follicular 
fluid and blood plasma at day of oestrus. From a total of 748 miRNAs used in the PCR 
panel 510 and 407 miRNAs were detected (with threshold cycle value of ≤35 in real 
time PCR analysis) in bovine follicular fluid and blood plasma respectively. 
 
 In follicular fluid 66 miRNAs were found differentially expressed at least two-fold 
differential expression at the significance level of p <0.05 (Figure 4.5). Compared with 
differentially expressed miRNAs derived from two groups, 34 miRNAs are up regulated 
and 32 miRNAs down regulated in hyperstimulated group comprised to unstimulated 
group.  In other hand circulatory miRNA  expression  of  blood plasma of day 7 profile 
of 26 miRNAs with at least two-fold differential expression at the significance level of 
p <0.05 (Fig. 4.6). Compared with the differentially expressed miRNAs derived from 
two groups, 15 miRNAs are up regulated and nine miRNAs down regulated in 
hyperstimulated group in comparison-unstimulated group. 
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Figure 4.5: The volcano plot of differentially expressed circulatory miRNAs in 
follicular fluid collected at day 0 (onset of oestrus) from hyperstimulated and 
unstimulated heifers. Respectively red and green colours represent up & down regulated 
miRNA, respectively with fold change ≥ 2; P ≤ 0.05(Points above the blue line).  
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Figure 4.6 The volcano plot of differentially expressed circulatory miRNAs in blood 
plasma collected at day 7 (onset of oestrus) respectively from hyperstimulated and 
unstimulated heifers. Respectively red and green colours represent up & down regulated 
miRNAs, respectively with fold change ≥ 2; P ≤ 0.05 (Points above the blue line). 
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4.4  Target prediction of different regulated miRNA 
miRNAs can post-transcriptionally regulate a large number of target genes and many 
target prediction tools based on various algorithms are available for target predicting 
miRNAs. TargetScan 6.2, PicTar and miRecords were used to predict gene targets of 
the deregulated miRNAs identified in this study. The list of top predicted target genes 
by miRNAs from follicular fluid and blood plasma analysis are listed in tables 4-1 &4-2 
respectively. 
 
 
Table 4.1: The list of differentially regulated miRNA of follicular fluid between 
hyperstimulated and unstimulated heifers with top predicted target genes 
(Experimentally validated targets are underlined) 
 
miRNA ID. Fold 
Change 
Predicted targets (Target scan /miRecords ) 
miR-643 51.9  KALRN, ZFP106, MEGF9, ANK3, PDZD7, SPTY2D1 
 
miR-212 40.6  ARHGAP32, CAPN8, MECP2, MMP9, RB1, TJP1 
 
miR-148b-5p 33.5  Not available 
 
miR-548j 24.1  ERBB2, MTA1,CCNB1, NFAT5, RALA, GULP1 
 
miR-132 22.7  RFX4, RICS , FGD4, MED28, ITCH, SAP30L 
 
miR-224-3p 14.1  Not available 
 
miR-129-3p 11.5  SEC14L1, TMEM136, SEC63, GLT25D2, PTAR1, 
 VTI1A 
miR-33b 10.7  ABCA1, ABCA1, CROT, CCNYL1, PCDH18, AKAP2 
 
miR-202-5p 6.6  Not available 
 
miR-155-3p 6.6  Not available 
 
miR-720 6.3  DCUN1D4, DNMT3A, ACVR1B, SAMD4B, FOXG1, 
QKI 
 
miR-374a 5.3  ACVR2B, N4BP2, MMP14, PARP8, SYNE1, ATAD2 
 
miR-1207-5p 5.2  CSRP1, FAM155B, PHF15, NACC1, ARC, CBX5 
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miR-182 4.9  ADCY6, IGF1R, MITF, RARG, RGS17, MITF 
 
miR-103 4.5  PLAG1, RAB1B, BACE1, CDCA4 , CRKL , EIF2C2 
 
let-7g 4.3  ACP1, BCL7A, BMP2K,DICER1, EIF2C4, EIF3J 
 
miR-106b 4  APP, BCL2, BMPR2, CRIM1, E2F2, BMPR2 
 
miR-191 4  Ccl9, CRP, IL6, TLR3, TMOD2, ZBTB34 
 
miR-542-5p 3.8  TBR1, HSPG2, NETO1, RCE1, MYLK2, RC3H1 
 
miR-22-5p 3.8  Not available 
 
miR-505-5p 3.6  Not available 
 
miR-550a 3.2  ADCY1, SHISA2, TMEM151B, ADPRH, GJC1, 
MEF2A 
 
miR-107 3.1  DICER1, ANO3, NF1, EIF5, ARIH2, FOXP1 
 
miR-595 2.8 SLC30A8 
 
miR-33a-3p 2.8   Not available 
 
miR-384 2.8  ASXL2, C18orf25, HDGF, VPS53, METAP2, MRE11A 
   
miR-374b 2.7  ACVR2B, N4BP2, MMP14, PARP8, SYNE1, ATAD2 
 
miR-30b 2.6  ACVR1, AP2A1, BECN1, BCL6, DOCK7, ELMOD2 
 
miR-31 2.6  CASR, CDKN2A, FOXP3, FZD3, HIF1A, MPRIP 
 
miR-106b-3p 2.5  Not available 
 
miR-940 2.4  SCN4A, STMN2, PDS5A, SEMA3F, NEDD4, UBE2F 
 
miR-495 2.3  ONECUT1, DDIT4, TNFRSF1B, ASB5, TNC, S1PR3, 
CTNND2 
miR-494 2.1  FGF16, HMOX1, PTEN, SCN3A, VSNL1, ONECUT1 
 
miR-550a-3p 2  Not available 
 
miR-452 -2.1  FAM8A1, DACT1, CASD1, PURA, IMMP2L, STAM2 
 
miR-24 -2.1  AURKB, CCNA2, CDKN2A, FEN1, MAPK14, 
SMAD3 
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miR-300 -2.1  HOOK3, LCORL, FILIP1L, VASH2, PARD6B, FNIP1 
 
miR-151-5p -2.2  WNT1, SEZ6L, NTRK2, N4BP1, PHF15, CASZ1 
 
miR-320a -2.6  HSPB6, MCL1, TAGLN, VIM 
 
miR-302e -2.7  CD83, CD44, DKK1,GBP3, BAZ1A,HERPUD1 
 
miR-525-5p -2.7  MAP3K13, DIRAS2, FAM102B, GNB5, YTHDF3,  
SCN3B 
 
miR-125a-3p -2.8  MEAF6, MTFR1, NIT1, POP1, P2RX7, SLC22A23 
 
miR-449a -2.9  DLL1, MYC, SIRT1, VEGFA, JAG1, E2F5 
 
miR-513c -3.1  SEPSECS, GXYLT1, PDE6A, CNTNAP2, NUFIP2, 
YTHDC2 
 
miR-23a -3.2  ATAT1, LMNB1, MET, SMAD4, TRIM63, TRPS1 
 
miR-206 -3.2  CAP1, CCSAP, CERS2, CHSY1, CNOT6, KCNE1 
 
miR-623 -3.3  ACSM2A, ILDR2, RNF169, MTMR7, ELAVL2,  
AP3M2 
 
miR-139-5p -3.4  FOXO1, TMF1, USP6NL, TBX1, SCAPER, NDRG2, 
DCBLD2 
 
miR-27b -3.4  ADORA2B, CTNNBIP1, CYP1B1, FOXO1, GCA, 
PEX7 
miR-125b-2-3p -3.6  Not available 
 
miR-378 -3.7  TOB2, HSPA12A, KCNIP2, KIAA1522,TSPAN17, 
PDIA4 
 
miR-125b -3.8  ABTB1, ADAMTS1, ANAPC16, ATP6AP1L, 
B3GALT4, CBX7 
 
miR-141 -4  BAP1, CLOCK, CTBP2, CTNNB1, DLX5, ELMO2 
 
miR-23b -4.1  ATAT1, FBXO32, HES1, IL6R,LMNB1, MDH2 
 
miR-621 -4.1  KLHL15, NFIB, CNOT6, ALDH1A2, ZC3H12B, 
VAMP7 
 
miR-190 -4.2  ERG, NEUROD1, BACH2, CEBPA, OSBPL6, SMAD2 
 
miR-382 -4.4  CAPN8, CNTN4, SEPT3 , TAGLN, VIM 
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miR-92a -4.5  VSNL1, MYLIP, MAP2K4, ITGA5, HIPK3, ENPP6 
 
miR-145 -4.7  ACBD3, CBFB, CCDC25, CCNA2, CLINT1, FBXO28 
 
miR-361-5p -5.2  RANBP17, DCTN6, ELOVL7, LACTB, SLC24A2, 
WNT7A 
 
miR-200a-5p -6.3  Not available 
 
miR-29b-2-5p -6.3  Not available 
 
miR-200c -6.4  ERBB2IP, ERRFI1, KLHL20, MARCKS, PLCG1, 
PPM1F  
 
miR-659 -8.3  GRN, RANBP17, DCTN6, ELOVL7, LACTB, 
SLC24A2 
 
miR-877 -12  TRIM10, TP53INP2, COL6A3, PDPN, NDUFA4, 
SORBS3 
 
miR-100 -13.9  FGF16 , FGFR3, IGF1R, MTOR, PLK1,RPTOR 
 
 
Table 4.2 The list of miRNA differentially regulated of blood plasma at day 7 onset of 
oestrus between hyperstimulated and unstimulated heifers with top predicted target 
genes (Experimentally validated targets are underlined ) 
 
 
miRNA ID Fold 
change 
Predicted targets (Target scan /miRecords ) 
miR-20b-3p 11 Not available 
  
miR-708-3p 8.4 Not available 
 
miR-26b-3p 5.1 KLHDC5, TET2, STRADB, CHORDC1, 
FAM98A, B3GNT5 
 
miR-598 3.8 Not available 
 
miR-32 3.2 ENPP6, VSNL1,BMPR2,CDKN1C,HIPK3,ITGA5 
miR-423-3p 2.9 RAP2C, PABPC1, PANX2, BCORL1, 
 
miR-130b-3p 2.8 Not available 
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miR-576-5p 2.8 Not available 
 
miR-221 2.7 BM, FOS, MMP1, PPP2R2A, SOD2,TBK1 
 
miR-1468 2.7 FUBP3, ST3GAL4, CUX1, STK40, PCBP2, 
TNRC6B 
 
miR-18a-3p 2.6 KRAS 
 
miR-24-2-5p 2.5 SLITRK1 
 
miR-181c 2.5 AICDA, CD69, ESR1, GATA6, VSNL1, NLK 
miR-103 2.4 PLAG1, RAB1B, BACE1, CDCA4 , CRKL , 
EIF2C2  
miR-34a 2.2 AXIN2, JAG1, MAP2K1, MYB, MYCN, WISP2 
miR-22 2.1 GRM5, CCDC67, MAX, FUT9, ESR1,  BMP7, 
let-7g 2 ACP1, BCL7A, BMP2K, DICER1, EIF2C4, 
EIF3J, 
miR-933 -2.8 BDNF, MEF2A , RAP2B, HCN4,COL12A1, 
KPNA1 
miR-125b -3 ADAMTS1, ANAPC16, B3GALT4, ERBB2, 
SGPL1, IGFBP3 
miR-410 -3.1 CPEB4, LCORL, LMTK2, TMEFF2, TMEM108, 
MKLN1 
miR-127-3p -3.1 BCL6, PRDM1, RTL1, XBP1,SETD8, FJX1 
 
miR-494 -3.2 FGF16, HMOX1, SCN3A, VSNL1, PTEN, 
FAM169A 
miR-147 -3.5 VEGFA, ZNF677, C13orf36, NF1, MAP4K3, 
PDPK1 
miR-99a-3p -5.4 Not available 
 
miR-134 -6.8 PUM2, GNAO1, RAB27A, ANKRD55, STAT5B, 
TCF21 
miR-153 -7 BCL2, FOXO1, MCL1, CLCN5, ANGPT1, HEY2 
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4.5 Characteristics of differentially expressed miRNAs on base of carrier   
 
To determine the extent to which circulatory miRNAs are associated with exosomes in 
follicular fluid and blood plasma one day 7 we used differential ultracentrifugation to 
purify circulating exosomes from cell free, platelet-poor of follicular fluid and blood 
prepared  from the same animals. The specificity of those isolation procedures were 
characterized at the protein level by the presence of CD63, a membrane protein, for 
exosomes, Ago2 protein in the non-exosomal fraction of the follicular fluid and blood 
plasma for both fractions. We confirmed recovery of exosomes consistent by CD 63 
protein blotting (Fig. 4.7). In mammalian cells, mature miRNAs are coupled with  
Argonaute (Ago) complexes that mediate messenger RNA silencing activity (Kim et al. 
2009). We hypothesized that these miRNAs are present within circulating Ago 2 
complexes. To determine if Ago 2 proteins are present in plasma, we performed 
immunoprecipitation followed by Ago2 protein blotting (Fig. 4.8).  
 
 
 
 
 
 
 
 
Figure 4.7 A representative western blot analysis of CD63 protein from purified 
exosomes by density gradient ultracentrifugation of follicular fluid (FF) and blood 
plasma (BP) collected at day 7 from hyperstimulated (Hyp) and unstimulated (Uns) 
heifers. 
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Figure 4.8  A representative western blot analysis of Ago2 protein from 
immunoprecipitated samples of follicular fluid (FF) and blood plasma (BP) collected at 
day 77 from hyperstimulated (Hyp) and unstimulated (Uns) heifers. 
 
 
 
Expression pattern of candidate miRNAs in both fractions of follicular fluid  and blood 
plasma was measured by qRT-PCR and the data are presented as raw Ct value in figure 
4.9 and 4.10 (follicular fluid ) and figure 4.11( blood plasma). Expression of miR-182 
was significantly higher in follicular fluid exosomal fraction of hyperstimulated heifers 
than unstimulated heifers, whereas other miRNAs showed no significant expression 
differences between treatment groups. While miR-182 (follicular fluid), miR-127-3P 
and miR-103 (blood plasma) were undetected in Ago2 fraction derived from both 
treatment groups, the expression of let-7g was not significant between the treatment 
groups. Expression analysis of underexpressed candidate miRNAs in exosomal fraction 
of blood plasma revealed that all miRNAs were detected in both treatment groups. 
Although there is no significant expression difference between treatment groups, all 
miRNAs had lower average Ct value in unstimulated heifers than hyperstimulated 
heifers. In case of Ago2 fraction of blood plasma, miR-134 and miR-147 had lower 
average Ct value in unstimulated heifers. While all miRNAs had significantly higher 
expression in exosomal fraction, interestingly miR-134 had average higher expression 
in Ago2 fraction of blood plasma. 
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Figure 4.9  Expression levels of miR-145, miR-200c, miR-361-5p and miR-877 in 
bovine follicular fluid coupled with exosomes (Exo) and Ago2 complex (Ago2)  from 
hyperstimulated (Hyp) and unstimulated (Uns) heifers (n = 4) are shown in raw Ct 
value.  Ct values of more than 35 were considered as undetected. 
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Figure 4.10  Expression levels of miR-100, miR-182, miR-22-5p, miR-92a and let-7g in 
bovine follicular fluid coupled with exosomes (Exo) and Ago2 complex (Ago2)  from 
hyperstimulated (Hyp) and unstimulated (Uns) heifers (n = 4) are shown in raw Ct 
value. Ct values of more than 35 were considered as undetected. 
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Figure 4.11 Expression levels of miR-147, miR-127-3p, miR-134, miR-103 and let-7g 
in bovine blood plasma coupled with exosomes (Exo) and Ago2 complex (Ago2)  from 
hyperstimulated (Hyp) and unstimulated (Uns) heifers (n = 4) are shown in raw Ct 
value. Ct values of more than 35 were considered as undetected. 
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4.6 Temporal differences in miRNA expression 
To evaluate the temporal expression of the selected miRNAs, we examined the temporal 
changes in expression level of candidate set of miRNAs in blood plasma at day 0, 3 and 
7 after the onset of oestrus in hyperstimulated and unstimulated.  The results (Fig. 4.12 
and Fig. 4.13) showed that the expression was significantly changed by the time points 
within the groups. Most miRNAs have similar expression pattern during oestrus period 
between the hyperstimulated and unstimulated group. The expression of miR-32 and 
miR-134 were down regulated on day 3 has significant different expression pattern 
compare to hyperstimulated group.  
 
Figure 4.12 Relative abundance of circulatory miRNAs in blood plasma at different 
time points after the onset of oestrus. *, P ≤ 0.05.  
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Figure 4.13  Relative abundance of circulatory miRNAs in blood plasma at different 
time points after the onset of oestrus. *, P ≤ 0.05. 
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4.7 Functional annotation  
 
miRNAs can post-transcriptionally regulate a large number of target genes and many 
target predication tools based on various algorithms are available for predicting the 
targets of selected miRNAs. To obtain an overview on the functional role of 
differentially expressed selected miRNAs, the predicted targets genes were then 
uploaded into the Ingenuity pathway analysis system (IPA) to identify the molecular 
networks (biological functions) and pathways based on the information in the IPA data 
base. IPA is a knowledgebase that contains approximately 3,000,000 biological and 
chemical interactions and functional annotations with definite scientific evidence, 
curated by expert biologists (Satoh 2012) . By uploading the list of target gene ID into 
the Core Analysis tool, the network-generation algorithm identifies focused genes 
integrated in a global molecular network. IPA calculates the score p-value that reflects 
the statistical significance of association between the genes and the networks by the 
Fisher’s exact test (Satoh 2012). Networks analysis data showed as many interactions 
between molecules in a given dataset and how they might work together at the 
molecular level. Networks are assembled based on gene/molecule connectivity with 
other gene/molecules by the target predicted genes of miRNAs up regulated in follicular 
fluid, down regulated in follicular fluid, up regulated in blood plasma and down 
regulated in blood plasma, respectively (Table . 4.3, 4.4, 4.5, 4.6).  
 
The analysis identified the most prominent canonical pathways related to the involved 
by the target pridicted genes of miRNAs up regulated in follicular fluid, down regulated 
in follicular fluid, up regulated in blood plasma and down regulated in blood plasma, 
respectively (Figure 4.14, 4.15, 4.16 and 4.17). Among these, cellular assembly and 
organization, cell cycle, carbohydrate metabolism, molecular transport, cellular 
development, cell signaling, cell death, cellular growth and proliferation, reproductive 
system development and function, embryonic development, amino acid metabolism, 
small molecule biochemistry, gene expression and ell to cell was dominated molecular 
networks.  
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Table 4.3 : Molecular networks involved by target genes of up regulated miRNAs in 
follicular fluid  
 
ID Molecules in Network Score Focus 
Molecules 
Top Functions 
1 ABCC9, ACAD9, Ahr-aryl 
hydrocarbon-Arnt Esr1,  ANKRD52, 
ARSB,  CHD2,  CSNK1G2,  DDX17,  
DDX18,  DSCR3,  ELOVL2,  ESR1,  
GATAD2B,  GJB2,  HNRNPA3, 
KCNJ1, KCNJ16,  Kcnj,  MBNL1,  
NACC1,  PHF5A,  PPP6C,  PPP6R2,  
RAB10,  RAP2C,  REEP6,  SALL1, 
SF3A1,  SUN2,    U2SURP,  WHSC1,  
ZBTB6 
43 33 Cellular Assembly 
and Organization,  
Cellular Function 
and Maintenance,  
RNA Post-
Transcriptional 
Modification 
2 ARIH2, CBX6, ENSA, FAF2, 
GATAD2A, LONRF1, MARCH3, 
MGA, MSX1, OS9, PCGF2, PCGF5, 
PEG10, PLEKHF2, Ras, RFWD3, 
RNF2, RNF38, RNF125, RNF144B, 
SCML1, SMARCE1, TFCP2L1, 
TLE4, UBE2, UBE2J1, UBE2K, 
UBE2L6, UBE2Q2, UBE2R2, 
UBE2W, UBE2Z, UBR3, YAF2, 
ZMIZ2 
43 33 Post-Translational 
Modification,  
Connective Tissue 
Development and 
Function,  
Embryonic 
Development 
3 ABCF2, BRWD1, C16orf72, CD3, 
CDR2L, CUL4A, DCAF5, DCAF10, 
DCUN1D4, ELAVL1, FAM120AOS, 
FAM73A, HIPK2, HNRNPA2B1, 
HS2ST1, KIAA0247, KIAA1199, 
NKTR, PGAM1, PRPF39, SCAF11, 
Shc, snRNP, SNRPD3, STK4, 
TANGO2, TMTC4, TSPAN9, TTPAL, 
UBE4A, VSIG10, WDR61, 
ZKSCAN1, ZNF362, ZNF562 
40 32 Carbohydrate 
Metabolism,  Drug 
Metabolism,  
Small Molecule 
Biochemistry 
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4 ABCE1,  Aconitase,  AGO1,  AGO2, 
AGO3, AGO4, CENPBD1, CNOT6L, 
DCP1A, DDX6, Eif2, EIF5, EIF1AX, 
EIF2A, EIF2AK3, ISCA2, Jnk, 
MIRLET7, PPAT, RC3H1, RNASEL, 
RNF13, RSU1, SFRP2, SFRP5, 
SH3BP5, SIX4, SIX5, TNRC6A, 
TNRC6B, UPF2, UPF3A, VANGL1, 
VANGL2, XRN1 
37 31 RNA Damage and 
Repair,  Infectious 
Disease,  Protein 
Synthesis 
5 AFF4, ARC, ARHGAP29, BEGAIN, 
CAB39, CCP110, CHD1, CRTC3, 
DUB, FLOT2, GRIA4, HERC2, 
KIAA0408, KIAA0947, LAPTM4A, 
LRP1B, MED13, MED20, MED29, 
mediator, NAV2, Pka, Rap, RAP2A, 
RAPGEF6, SIK2, TADA2B, 
TRAP/Media, TUBB4A, USP8, 
USP25, USP42, USP45, USP47, 
ZNF275 
36 30 Cell-To-Cell 
Signaling and 
Interaction,  
Nervous System 
Development and 
Function,  Cell 
Cycle 
 
 
 
Table 4.4  Molecular networks involved by target genes of down regulated miRNAs in 
follicular fluid 
 
ID Molecules in Network Scores Focus 
Molecules 
Top Functions 
1 ANO6, AP1AR, BNC2, C19orf55, 
C1orf198, C3orf52, C5orf51, C6orf62, 
CCNJ, CDR2L, DRAM2, EFCAB14, 
ELAVL1, ERBB2, FAM102B, FAM73A, 
GUCD1, HECA, HERPUD2, LACTB, 
MBD6, PHTF2, PQLC1, RB1, RBAK, 
SKIDA1, SLC41A1, SLC48A1, 
TBC1D22B, TMEM209, TTPAL, 
VSIG10, ZFAND1, ZNF362, ZNF529 
35 35 Cancer,  Cell 
Cycle,  Cell 
Death and 
Survival 
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2 ATP5G3, BCL11A, BRSK2, CCNYL1, 
CD84, CD5L, CDK16, CENPBD1, 
CORO2A, CRTAM, DCP1A, HINFP, 
HIPK3, IGF1R, INTERLEUKIN, 
KDM5A, KIF2A, MIF4GD, NFATC2IP, 
NPAT, SCAF11, SMARCD2, SMG1, 
SREK1, SRSF1, SRSF4, TBL1XR1, 
TFEC, TNRC6A, TRA2B, XRN1, 
YTHDC1, ZBTB33, ZMYM3, ZRANB2 
34 34 RNA Post-
Transcriptional 
Modification,  
Cellular 
Development,  
Connective 
Tissue 
Development 
and Function 
3 BAI3, CALCRL, CCR8, CELSR2, 
CHRM5, ELTD1, EMR3, FZD3, FZD5, 
FZD10, GABBR2, Gpcr, GPR3, GPR37, 
GPR56, GPR85, GPR107, GPR124, 
GPR126, GPR155, GPR158, GPR160, 
GPR180, GPR137C, GPRC5A, LGR4, 
LPAR4, LPAR6, LPHN1, LYST, PCNX, 
PTGFR, SLC52A1, SSTR1, SSTR3 
34 34 Cell-To-Cell 
Signaling and 
Interaction,  
Cancer,  
Endocrine 
System 
Disorders 
4 60S ribosomal subunit, AARS2, 
ANKRD26, BRCA1, C7orf26, CDK4, 
CUX2, EML3, ERG, FOXD2, GDF10, 
HDGF, ING2, KIAA1109, LIMD2, 
MAP2K4, MBLAC2, MET, NKX2-4, 
PAXBP1, ROCK2, RPL15, RPL37, 
SIRT5, SMAD2, SMAD3, SMAD4, 
SMO, TMEM219, TRMT10C, TSEN54, 
YWHAQ, ZCCHC14, ZDHHC5, 
ZNF280D 
34 34 Connective 
Tissue 
Development 
and Function,  
Embryonic 
Development,  
Organ 
Development 
5 AEBP2, CDK2-CyclinE, COL14A1, 
DDX52, EPC2, FIBP, GMNN, HES2, 
HOXC8, IGF2BP1, IMPA2, IMPDH1, 
JARID2, KANSL2, MOB1B, MORC3, 
MSL3, MTUS2, MYC, OGT, PDZD2, 
PERP, PGAP1, PHF20, PHF20L1, 
PLSCR4, PMP22, RARRES1, SEC31B, 
STK38L, TBC1D1, TBC1D4, TMEM33, 
UTP15, ZXDB 
33 34 Dermatological 
Diseases and 
Conditions,  
Hereditary 
Disorder,  
Organismal 
Injury and 
Abnormalities 
 
 
 
 
Table 4.5: Molecular networks involved by target genes of up regulated miRNAs in 
blood plasma on day 7 onset of oestrus  
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ID Molecules in Network Score Focus 
Molecules 
Top Functions 
1 alpha-N-acetylneuraminate alpha-
2, 8-sialyltransferase, ANK1, 
ANO3, B3GNT5, CBX7, 
CCDC50, DBT, EDA, FRYL, 
KLF3, KPNA3, KPNA4, MEFV, 
MGA, NFkB (complex), NUP50, 
OLFM4, OTUD7B, PCGF2, 
PCGF5, PELI2, PHC3, 
PTPLAD1, RAB31, ST8SIA1, 
ST8SIA3, ST8SIA4, SYT6, 
SYT10, UBE4A, UMOD, VOPP1, 
YAF2, ZDHHC3, ZFAND5 
46 33 Carbohydrate 
Metabolism,  
Lipid 
Metabolism,  
Small Molecule 
Biochemistry 
2 ADNP, AGO1, AGO2, AGO3, 
AGO4, AKAP8, BAZ2A, C6, 
CNTNAP1, DICER1, DSG1, Eif2, 
EIF5, EIF1AX, FMR1, GNS, 
ING3, MAP4, NCK1, NCKAP5, 
OTUD4, P38 MAPK, PARP11, 
PHACTR2, PPM1A, RNase A, 
RUNX1T1, SALL1, SEPT6, 
SNX3, STAU2, SUN2, TBKBP1, 
TFCP2L1, TRIM33 
42 32 Infectious 
Disease,  Cell 
Death and 
Survival,  
Embryonic 
Development 
3 Ahr-aryl hydrocarbon-Arnt-Esr1, 
ANKRD52, CDK8, CPNE3, 
CSNK1G2, DDX18, DUB, 
EPB41L5, ESR1, FAF2, G3BP2, 
HNRNPA3, MAML1, MED20, 
mediator, NUFIP2, OS9, PHF5A, 
PJA2, PPP6C, PPP6R2, RAP2C, 
RDX, SEL1L, THRAP3, TMX1, 
TRAP/Media, U2SURP, UBXN4, 
USP14, USP29, USP42, USP46, 
USP47, ZNF275 
41 31 RNA 
Trafficking,  
Post-
Translational 
Modification,  
Cancer 
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4 AChR, AFF4, BMP3, BTRC, 
Calmodulin, CAST, CLOCK, 
CYP26A1, ELL2, FBXW11, 
GLIS3, HCFC1, Hedgehog, IHH, 
IRF2BP2, KIAA0947, MAP9, 
MSL2, NECAB1, NEUROD1, 
NPAS2, NUP62CL, OGT, 
PCSK2, PER3, PHF20, 
Proinsulin, RIMBP2, RNF19A, 
STXBP4, SUFU, TIP60, TRIM26, 
VAMP1, VPS4A 
38 30 Endocrine 
System 
Development 
and Function,  
Tissue 
Morphology,  
Cellular 
Development 
5 ARIH2, BTN1A1, CALD1, 
CAPZA2, CCSER2, CDC14A, 
Cytoplasmic Dynein, DISC1, 
DYNC1LI1, ENSA, FEZ1, 
FNDC3A, FOXN2, Gamma 
tubulin, GLUD1, HERC2, 
KATNAL1, MZT1, NDEL1, 
PAIP2, PAPSS2, SERBP1, 
SLC31A1, SMEK2, SP4, TAF1D, 
TRIB2, trypsin, TUBGCP3, 
UBE2, UBE2J1, UBE2R2, Vegf, 
ZBTB10, ZNF197 
37 30 Cellular 
Movement,  
Nervous 
System 
Development 
and Function,  
Cardiovascular 
Disease 
 
 
 
 
 
 
Table  4.6: Molecular networks involved by target genes of down regulated miRNAs in 
blood plasma on day 7 onset of oestrus  
 
ID Molecules in Network Score Focus 
Molecules 
Top Functions 
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1 AFF2, ANK3, ATP10D, BAZ2A, 
CEBPG, CREB5, DNM3, Dynamin, 
ENAH, GRB2, GTPBP2, Hd-
perinuclear inclusions, ITSN2, 
KIAA1549L, LNPEP, MYO18A, 
NFASC, PSTPIP2, RAB22A, 
RAB8B, RCOR1, SEPT11, 
SH3BP4, SLC6A15, SLCO2A1, 
SMARCD2, SNX18, TEF, TES, 
TFAP2B, UNKL, WDR1, ZBTB37, 
ZNF217, ZNF609 
42 33 Cardiovascular 
Disease,  
Developmental 
Disorder,  Cell Cycle 
2 ANKRD50, APP, C6orf106, 
CCDC149, DIRAS1, EBF4, 
FAM213A, HDDC3, HIC2, 
LURAP1L, NAV1, NECAB3, NPL, 
OLFML2A, PCDHGA12, 
PCDHGC5, PRRC1, PYROXD1, 
RABL3, RAPGEFL1, RASL12, 
RASL10B, RIMS4, SERAC1, 
SERTM1, SLAIN2, TBC1D20, 
TET3, TMCC2, TMEM180, 
TSPAN12, VASH2, ZFYVE1, 
ZNF343, ZNF483 
41 35 Cell-To-Cell 
Signaling and 
Interaction,  Cellular 
Assembly and 
Organization,  
Nervous System 
Development and 
Function 
3 ANK1, ANO3, cacn, CACNB1, 
CACNB3, CD300LF, CGREF1, 
FAM46A, GFPT2, HDLBP, 
INTERLEUKIN, KCNB1, KCNS3, 
KCTD6, KLF3, MFHAS1, N-type 
Calcium Channel, NFkB (complex), 
NKIRAS2, PHF21A, POU4F1, 
RHEBL1, RUSC2, SLC1A5, 
SLC2A12, SLC6A17, SMEK1, 
SNAP25, SPTB, ST18, SYN3, 
Syntaxin, TBX4, VAMP2, 
ZNF385A 
36 30 Neurological Disease,  
Skeletal and Muscular 
Disorders,  Cell-To-
Cell Signaling and 
Interaction 
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4 ARID3A, ARID3B, ARID4A, 
ASXL1, CBX7, Cdc2, CDC42SE1, 
CEP164, DAAM2, DOCK3, DVL3, 
E2F2, E2F3, E2f, HERC3, HNF4α 
dimer, HOXB3, ING2, Jnk, 
MAP4K3, MAP4K5, MATN2, 
PCGF6, PHC2, RAPGEF5, 
RNF144A, RNF144B, RYBP, 
SCML1, SCML2, Stat1/3, THAP2, 
UBE2L3, VANGL1, VANGL2 
36 30 Cellular 
Development,  
Connective Tissue 
Development and 
Function,  Cell Cycle 
5 ABTB1, BCL11A, C17orf59, 
CBFB, CD5L, CORO2A, Ctbp, 
DNMT3A, DYNLT3, ETV6, 
FAM65B, GATAD2A, histone-
lysine N-methyltransferase, IGF1R, 
IKZF1, IKZF2, IKZF4, KDM5A, 
MAPK1IP1L, Mi2, MUL1, PERP, 
Pias, SATB1, SETD7, SETD8, 
SLC4A10, SUV39H1, TDG, TFEC, 
Top2, TSHZ1, UBE2I, VPS37B, 
VPS37C 
36 30 Gene Expression,  
Cell Morphology,  
Cellular Assembly 
and Organization 
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Figure 4.14 The most prominent canonical pathways related to the involved genes 
targeted by up regulated miRNA in follicular fluid. The bars represent the p-value for 
each pathway. The orange irregular line is a graph of the ratio (genes from the data 
set/total number of genes involved in the pathway) for the each pathway. 
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Figure 4.15 The most prominent canonical pathways related to the involved genes 
targeted by down regulated miRNA in follicular fluid. The bars represent the p-value 
for each pathway. The orange irregular line is a graph of the ratio (genes from the data 
set/total number of genes involved in the pathway) for the each pathway. 
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Figure 4.16 The most prominent canonical pathways related to the involved by genes 
targeted by up regulated miRNA in blood plasma collected at day 7. The bars represent 
the p-value for each pathway. The orange irregular line is a graph of the ratio (genes 
from the data set/total number of genes involved in the pathway) for each pathway. 
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Figure 4.17 The most prominent canonical pathways related to the involved by genes 
targeted by down regulated miRNA in blood plasma collected at day 7. The bars 
represent the p-value for each pathway. The orange irregular line is a graph of the ratio 
(genes from the data set/total number of genes involved in the pathway) for each 
pathway. 
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5 Discussion  
 
5.1 Polymerase chain reaction inhibitors in body fluid 
A possible  source of variation in miRNA array data  from body fluids such as blood 
serum or  plasma is the RNA isolation procedure and the presence of inhibitors that 
affect the cDNA synthesis and/or real time PCR reactions (Blondal et al. 2013). As cell-
free miRNA concentrations are low in these samples, it is tempting to try to maximize 
the amount of sample used per reaction. In practice increasing the amount of RNA input 
could also lead to an increased concentration of PCR enzyme  inhibitors such as heparin 
which may be derived from the bio-fluid or introduced via reagent carry-over during 
sample preparation and suboptimal RNA isolations. Therefore reliable results in real-
time RT-PCR array and microarray analysis depend on the quality of the RNA sample. 
Traditionally, RNA integrity is determined by denaturing agarose gel electrophoresis, 
where intact RNA is indicated by a 2:1 ratio of the bands for 28S and 18S rRNA. 
Generally RNA purity is determined by spectrophotometrically. The ratio of 
absorbances at 260 nm and 280 nm (A260:A280) determines the degree of protein 
contamination and the A260:A230 ratio is used to identify any contamination by 
organic solvents. These ratios should be >1.8. Standard methods for measurement of the 
RNA yield and quality are inappropriate for use with bio-fluid samples. The presence of 
carrier RNA in these samples makes measuring the low levels of endogenous RNA by 
OD260 impossible. Even if the carrier was not included during the isolation, the RNA 
concentration in the eluate would still be too low for reliable OD260 quantification on a 
NanoDrop or other spectrophotometer. Therefore, an extensive alternative quality 
control of total RNA has been implemented to secure technical soundness. In order to 
check the quality of total RNA extracted from follicular fluid and blood plasma, we 
investigated two crucial parameters- presence of typical miRNAs which are abundantly 
present in bio-fluids and absence of inhibitors of cDNA synthesis and the PCR enzyme. 
These two parameters were investigated using a small set of single qPCR assays where 
cDNA was synthesized with different total RNA input (e.g. 0.5 µl, 1.0 µl, 2.0 µl, and 4.0 
µl in a 10 µl reaction) to make a dilution curve. This pre-examination allowed us to 
discard these samples which fail to show linear amplification from depending on the 
RNA input. 
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5.2  Extracellular miRNAs expression profile in follicular fluid induced changes by 
COH  
Follicular fluid is a product of both the transfer of blood plasma constituents that cross 
the blood follicular barrier and of the secretory activity of granulosa and thecal cells 
(Fortune 1994). The follicular fluid is rich in metabolites, proteins, cytokines, vitamins, 
growth factors, and hormones. Some studies have also shown that the follicular fluid 
contains essential substances involved in follicle growth, oocyte fertilization and 
spontaneous abortion. The metabolite composition of the follicular fluid is correlated 
with the developmental competence of the human oocyte (Wallace et al. 2012), and 
some proteins in the follicular fluid that play roles in glucose metabolism, lipoprotein 
metabolism, cell proliferation, and insulin resistance have been found to be associated 
with polycystic ovary syndrome (Dai and Lu 2012). For example, increased ghrelin 
levels in the follicular fluid negatively affect human oocyte quality and in vitro embryo 
development (Li et al. 2011a). 
 
The present study investigated for the first time, the effects of FSH-hyperstimulation 
treatment on expression profile of circulatory miRNA in cell-free bovine ovarian 
follicular fluid and blood plasma during estrus days. The primary objective of this study 
was to comprehensively define the dynamic changes in expression of circulatory 
miRNA in follicular fluid induced by COH during oestrus days. Our data showed COH 
induced change of circulatory miRNA expression profile in follicular fluid as 
microenvironment of oocyte maturation. Growth of the follicle encompasses 
enlargement of the oocyte, replication of follicular cells, and formation and expansion 
of a central follicular antrum or cavity. In vivo, follicle-stimulating hormone (FSH) in 
particular stimulates follicular growth. COH stimulates the ovaries by 
supraphysiological levels of gonadotrophins (FSH, GnRH) to induce multiple follicle in 
single ovulation species including humans and bovine. 
 
 
Moreover it has been suggested that specific miRNAs may have crucial roles in the 
initiation and/or progression of bovine fertility through their effects on various 
molecular pathways. A better understanding of miRNA expression in different follicular 
stage may uncover novel molecular pathways, or novel mechanisms of activation for 
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known pathways associated with folliculogenesis. Role of gonadotrophins to activate or 
deactivate of steroid hormones production in theca and granulosa cells is a well 
established fact (Whirledge and Cidlowski 2010). miRNA profiling revealed the 
upregulation of a small subset of miRNAs in female mice deficient in estrogen receptor 
α(ERα) and  conversely, estradiol treatment of ovariectomized female mice showed 
downregulation of some miRNAs in the uterus, which is an estrogen target organ 
(Macias et al. 2009).  
 
Functional analysis in a human granulosa cell tumors -derived cell line cells showed 
that miR-24, miR-132, miR-320, miR-222, miR-520c-3p, miRNA-193b, and miRNA-
483-5p regulated hormone production in granulosa cell (Sang et al. 2013). Their 
reported  reveals the existence of miRNAs in human cell-free follicular fluid and 
demonstrates that some highly expressed miRNAs many have key functions in 
steroidogenesis in vitro and are associated with PCOS in vivo (Sang et al. 2013). 
 
Studies have shown that miRNAs exist in serum (Mitchell et al. 2008), urine (Chan et 
al. 2003), saliva (Chan et al. 2003), milk (Kosaka et al. 2010) and semen (Li et al. 2012) 
and that these circulating miRNAs can be used as biomarkers for various cancers (Chen 
et al. 2008, Hu et al. 2010, Yu et al. 2012), cardiovascular diseases (Ai et al. 2010, Li et 
al. 2011b), and metabolic diseases (Zampetaki et al. 2010, Zhao et al. 2011). Until now, 
however, no studies have been carried out on the expression miRNAs in bovine 
follicular fluid under COH. In this study, we have used real time PCR assay to identify 
several miRNAs in the follicular fluid that appear to have important functions in a 
variety of cellular processes. Previous studies demonstrated that circulating miRNAs in 
serum and other body fluids were found to exist in both microvesicles and AGO2 
complex (Arroyo et al. 2011, Turchinovich et al. 2011). Consistent with these studies, 
we evidenced expression of the follicular fluid miRNA being coupled in microvesicles 
and AGO2 protein complex. 
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5.3 Circulatory miRNAs expression affected in blood plasma by hyperstimulation  
 
Plasma miRNAs are a promising source of potential biomarkers for non-invasive 
diagnosis of many diseases. Most plasma miRNA biomarkers associated with different 
pathologies that have been discovered so far are also found to be expressed at high 
levels in blood cells. The alterations in blood cell counts and specimen handling 
procedures may have an impact on the candidate circulating cell-free miRNA biomarker 
specificity, as the changes observed may be caused by physiological changes rather than 
the disease (Pritchard et al. 2012, Rekker et al. 2013) . 
 
Considering the temporal miRNA expression profile  miRNAs (miR-125a, miR-199a-
3p, miR-125b, miR-99a, let-7c, miR-145, miR-31, miR-202 and miR-27b) with 
decreased expression and miRNAs (miR-503, miR-21, miR-29b, miR-142-3p, miR-34a, 
miR-152, miR-25 and miR-130a) with increased expression between the follicular and 
luteal stages in ovine ovarian tissues were descried (McBride et al. 2012). On the other 
hand a recent study reported no differences in plasma miRNA expression levels 
between the menstrual cycle time-points. Based on this finding, that miRNA levels 
detectable in plasma of healthy women are not significantly altered by the processes 
occurring during the menstrual cycle. It is probable that miRNA expression changes in 
tissues are necessary for the local gene expression regulation but the fluctuations are 
insufficient to alter the miRNA patterns detectable in circulation (Rekker et al. 2013). 
 
miRNAs regulate many cellular processes that also occur during the cyclic changes in 
the endometrium and other tissues. Several studies have demonstrated differential 
expression of miRNAs in endometrium during the estrus cycle and have emphasised 
their role in endometrial differentiation into its receptive state (Altmae et al. 2013; 
Kuokkanen et al. 2010; Sha et al. 2011).  These studies reported up to seven fold 
differences in miRNA expression levels between receptive (LH day 7) and non-
receptive (cycle day 12 or LH day 2) endometrium, where miR-30d, miR-30b, miR-31, 
miR-193a-5p, miR-203 showed up-regulation and miR-503 down-regulation in 
receptive endometrium (Altmae et al. 2013; Kuokkanen et al. 2010; Sha et al. 2011). 
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Our result first time showed after COH significant changes of the circulatory miRNA 
profile in blood plasma, induced by the supraphysiological progesterone concentrations 
associated with ovulation induction. We hypothesise circulatory miRNAs expression 
affected in blood plasma on day 7 past estrus by hyperstimulation on basis of 
physiological changes in tissue that effected by hyperstimulation(figure 4.6).  The 
supra-physiological concentrations of steroid hormones, secreted by a higher  number of 
corporalutea during the early luteal phase, seems to be the main cause of luteal phase 
defect in hyperstimulated IVF cycles in human and bovine that  in term directly inhibit 
LH release via negative feedback actions at the hypothalamic−pituitary axis level 
(Fauser and Devroey 2003). Indeed, expression levels of miRNAs seem to be more 
important in the preimplantation embryos, around the MET rather than at the maturing 
oocyte stages. Recent studies have demonstrated that changes in global miRNA 
expression pattern in circulating body fluids and cells are influenced by several 
demographic and normal physiological variables. Age (Sredni et al. 2011), gender 
(Duttagupta et al. 2011) have been shown to be some of the factors contributing to 
miRNA expression level differences (Rekker et al. 2013) .  
 
 Meanwhile, different expression profiles have been obtained for other miRNAs during 
early embryo development. Some of them showed higher levels in the oocyte while 
others showed a very weak expression level throughout early development and an 
augmentation only at the blastocyst stage (Tripurani et al., 2010). A negative effect of 
hyperstimulation on embryo development rate was  reported, as evidenced by the 
greater proportion of morula than blastocysts flushed from the hyperstimulated heifers 
at day 7 compared to unstimulated heifers (Gad et al. 2011).  Otherwise oviducts were 
unable to support migration of oocytes and were therefore non-functional and the uterus 
had a decrease for epithelium compared to normal uteri (Gonzalez and Behringer 2009). 
On other studies in the mouse uterus, progesterone treatment significantly increased the 
expression of Dicer1 and Exportin-5, two components of the miRNA biogenesis 
pathway (Cochrane et al. 2012; Nothnick et al. 2010). This suggests developmental 
retardation of embryos developing under hyperstimulation conditions. In addition, the 
increasing expression level of the immature forms of miR-21 (primary and precursor) at 
the 2-cell embryo, together with its sensitivity to a-amanitin treatment, indicates the 
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possibility that they represent a portion of the minor transcriptional activation (Mondou 
et al. 2012) and pregnancy stage (Gilad et al. 2008). 
 
5.4  Expression pattern of candidate circulatory miRNAs in exosomes and Ago2 
fraction 
In this work, we addressed questions regarding, the possible origin and biological 
function of circulating extracellular miRNA in bovine follicular fluid and blood plasma. 
Cells release microvesicles and exosomes that can transfer biological materials over 
long distances when released into the bloodstream, and potentially modulate cell 
function at target cells.  Microvesicles and exosomes are present in a variety of body 
fluids in health and disease (urine, blood, and ascites fluid), suggesting that they have a 
role in normal homeostasis and are released under disease conditions (da Silveira et al. 
2012). 
  
As major tool for the characterization of miRNAs on basis of carrier differential 
ultracentrifugation and Ago2 immunoprecipitation were used to isolate cell-secreted 
exosomes or miRNA/Ago2 complexes from ovarian follicular fluid and blood plasma.  
We utilized individual miRNA assays for three selected miRNAs .These miRNAs were 
all detected as differentially regulated miRNA in bovine follicular fluid and blood 
plasma. Once we confirmed the efficient recovery of exosomes and Ago2 protein 
complex from follicular fluid, we investigated the expression pattern of candidate 
miRNAs in both fractions (figure 4.7 and 4.8). By using a systemic approach, we have 
revealed that there are at least two populations of circulating miRNAs in follicular fluid 
and blood plasma, namely exosomes and Ago2 complex associated. The specificity of 
exosomes isolation were confirmed by the presence of CD63 in isolated exosomes 
(Gallo et al. 2012; Logozzi et al. 2009; Valadi et al. 2007). It has been well documented 
that platelet-derived exosomes are enriched in CD63. However, this tetraspan protein is 
also found in exosomes from other cell types. Tetraspan proteins have been implicated 
in adhesive as well as costimulatory and signaling functions. To support the hypothesis 
that along with exosomes Argonaute2 protein complex also carry a sub set of miRNA in 
follicular fluid, we checked the presence of Ago2 protein abundance in non-exosomal 
portion of follicular fluid. Recent reports have suggested that a common source of 
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unwanted bias in miRNA profiles in serum or plasma samples is cellular contamination 
of the samples with various cell types from blood or their donor cells (McDonald et al. 
2011). Expression pattern of candidate miRNAs was measured by qRT-PCR and 
resulting data are shown as raw Ct value in Figure 4.9, 4.10 and 4.11. Our data, 
demonstrated miR-182 in follicular fluid,  miR-127-3p and miR-103 was not detected in 
Ago2 complex portion,  that conduct shows that  not all extracellular miRNA are 
associated with the Ago2 complex. On the other hand, miR-34a, miR-32 miR-221, miR-
410, miR-494 and miR-153 were not detected in both portions of exosomal and Ago2 
complex in blood plasma.  Expression of these candidates in Ago2 fraction of follicular 
fluid shows aberrant pattern.  
 
Expression data showed not all selected miRNAs were present in the Ago2 complex 
portion and exosomal portion. We validated exosomes mediated cell-cell 
communication within follicular microenvironment; we examined uptake of exosomes 
and resulting increase of endogenous miRNA level and subsequent alteration of mRNA 
levels in follicular cells form of exosome between follicular cells. We have investigated 
the ability of granulosa cells to take up exosomes isolated from follicular fluid in vitro. 
The presence of exosome or non-exosome mediated transfer of miRNA in the bovine 
follicular fluid, and oocyte growth dependent variation in extra-cellular miRNA 
signatures in the follicular environment was shown (Sohel et al. 2013). Similar studies 
have also shown the stability of circulating serum miRNAs (Gilad et al. 2008), breast 
milk exosomal miRNA at room temperature and other multiple freeze-thaw cycle (Zhou 
et al. 2012). 
 
We hypothesize that miRNAs absent in exosomes and Ago2/miRNA complex are 
carried by HDL transport within the developing follicle. This may be critical to normal 
oocyte development and emphasizes the need for further studies to elucidate the 
mechanisms that regulate intrafollicular circulatory miRNA transport during 
folliculogenesis. A paradigm of autocrine and paracrine miRNA signalling through 
exosomes cannot be excluded.  Recent studies demonstrate circulatory miRNA are 
associated with HDL (Vickers et al. 2011). The remarkable study provided the first clue 
to an important relationship that exists between HDL particles and the ovarian follicle 
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(Trigatti et al. 1999). This study was designed before the novel finding that circulatory 
miRNA are associated with HDL.  
 
The physiological role of circulating miRNAs coupled with HDL particles in the 
developing follicle and embryo has remained obscure. HDL appears to be the dominant 
lipoprotein particle in follicular fluid during human folliculogenesis (Fujimoto et al. 
2010) . The physiological role of HDL in the developing follicle and continuing 
pregnancy is well established that both HDL and low-density lipoprotein (LDL) deliver 
cholesterol to the corpus luteum as a substrate for progesterone synthesis (Azhar et al. 
1998, Reaven et al. 2000, Roy and Belanger 1992).  
 
Oxidative stress caused by  using ART method is main open issue. It is also well 
established that HDL particles can moderate reactive free radicals, thereby limiting 
oxidative damage to cells and other lipoproteins (Decossin et al. 1995, Klimov et al. 
1993, Kunitake et al. 1992, Mackness and Durrington 1995, Parthasarathy et al. 1990). 
Numerous animal models illustrating the effects of HDL metabolism on reproductive 
outcomes suggest that HDL cholesterol metabolism may be important in human and 
bovine reproduction (Aiello et al. 2003, Bujo et al. 1994, Christiansen-Weber et al. 
2000, Fujimoto et al. 2010, Miettinen et al. 2001, Nimpf et al. 1989, Trigatti et al. 1999, 
Yesilaltay et al. 2006). Browne et al., demonstrated by the scavenger receptor class B 
type I (SR-BI KO) mouse model, the role of serum and follicular fluid  HDL particles 
on the reproductive potential of the human oocyte using embryo morphologic 
parameters as surrogate biomarkers for oocyte quality during IVF.  Their  findings 
showed  negative correlations between follicular fluid HDL cholesterol and Apo AI 
levels with embryo fragmentation evaluated after 72 h of IVF culture (Browne et al. 
2008).  
 
5.5 Predicted target genes and network analysis 
Bioinformatics analysis revealed that several important target genes of the differently 
expressed miRNAs are related to PTEN signaling, neurotrophin signaling pathway, 
HGF signaling pathway, VEGF signaling pathway, TGF-β signaling pathway, axonal 
Discussion   85 
 
guidance signaling and Wnt ß-catenin signaling pathways to be the dominant ones 
(Figure  4.14, 4.15, 4.16 and 4.17). 
As previously mentioned, miR-132, miR-24, miR-320 and  miR-520c-3p were found to 
regulate steroidogenesis in vitro (Sang et al. 2013). miRNA-132 is known to lead to the 
activation of nuclear factor κB and to the transcription of IL-8 and monocyte 
chemoattractant protein-1 (MCP-1) in both primary human preadipocytes and 
differentiated adipocytes (Strum et al. 2009). In addition, serum miRNA-132 levels are 
significantly decreased in gestational diabetes mellitus, suggesting that miRNA-132 
may be involved insulin secretion (Zhao et al. 2011). miRNA-132 is also known to have 
key roles in immune system development, metabolic pathways and  neurodevelopment 
(White and Giffard 2012). First identified a partial amino acid sequence from 
transforming growth factor beta 1 (TGFB1) purified from blood platelets, numerous 
studies have highlighted the role of this peptide as a modulator of cell growth, 
proliferation and differentiation in many types of cells and  tissues (Gilchrist and Ritter 
2011, Nagamatsu et al. 2012). It is also thought that TGF proteins are involved in the 
regulation of oocyte and embryonic growth and development (Juengel and McNatty 
2005).   
 
Vascular endothelial growth factor (VEGF) has been reported to be involved in oocyte 
maturation as it enhances vascularisation via stimulation of the vascular endothelial 
growth factor receptor (VEGFR) leading to migration and differentiation of blood 
vessels, thereby increasing the availability of serum factors such as follicle stimulating 
hormone (FSH) and LH. The EGF-like growth factor amphiregulin (AREG), functions 
to mediate the LH induction of ovulation in pre-ovulatory follicles and granulosa cell 
differentiation (Ashkenazi et al. 2005, Hsieh et al. 2007, Park et al. 2004b) Another 
important factor is growth differentiation factor 9 (GDF9), which is a member of the 
TGF-β family and has been shown to be expressed by mammalian oocytes throughout 
ovulation beginning in pre-antral follicles and is involved in the selection of primordial 
follicles for further development beyond the primary follicle stage (Aaltonen et al. 
1999) . 
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Other signalling factors which have been shown to impact ovarian cell function and 
organization are members of the Wnt and Frizzled family of signalling molecules. Wnts 
are secreted signalling molecules that act to control many processes influencing cell 
proliferation and differentiation. Wnts act by binding to G-protein-coupled receptors of 
the Frizzled family stimulating signalling cascades that impact the development and 
function of reproductive organs. Wnt-4 provides an example of the importance of such 
signalling factors, as mice null for Wnt-4 have sex reversed ovaries and express genes 
characteristic of testes development such as Müllerian inhibiting substance (Vainio et 
al. 1999). Wnt-4 is expressed in primary follicle granulosa cells and has been shown to 
have increased expression following the LH surge. Although it is known that the 
Wnt/Frizzled signalling pathway is important for the growth and development of 
ovarian follicles, the regulatory mechanisms of these molecules as well as other 
potential downstream targets needs to be further investigated (Richards et al. 2002).
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6 Summary  
 
 
Controlled ovarian hyperstimulation (COH) stimulates the ovaries by 
supraphysiological levels of gonadotropins to induce the growth of multiple follicle in 
single ovulation species including humans and bovine. In bovine, in order to increase 
the number of offspring during the lifetime of the individual, female animals with high 
genetic value are typically stimulated with gonadotropin hormones to persuade the 
ovulation of a variable but many number of follicles. For several years, the most 
common use of embryo transfer has benefited from the establishment of newer, more 
efficient methods for the superovulation of donors, embryo retrieval ⁄ transfer by low-
invasive methods as well as by the better, simpler and more effective cryopreservation 
methods in human and bovine. However despite significant advances in assisted 
reproduction technology protocols in humans and bovine, pregnancy rates are still 
relatively low and have not increased significantly in the last decade. 
 
 MicroRNAs are post transcriptional regulators that influences expression of hundreds 
of genes in numerous biological processes including development. Circulatory 
noncoding small RNAs (miRNAs), which are present in various body fluids, are 
reported to be potentially used as biomarkers for disease and pregnancy.  The present 
study was preformed to investigate the effect of ovarian hyperstimulation on the 
expression pattern of circulatory miRNA in follicular fluid and blood plasma. For this, 
Simmental heifers (n=12) were synchronized using a standard synchronization protocol 
and six of them were hyperstimulated using FSH. Following this, while blood samples 
were collected at 0 (onset of oestrous), 3rd and 7th day, follicular fluid samples were 
aspirated from dominant follicles at the day 0 from all animals by ovum pickup. Total 
RNA isolation was done using miRNeasy® Mini kit. From each follicular fluid  and 
blood plasma portion, 100 ng of total RNA was reverse transcribed using Universal 
cDNA synthesis kit. The resulted cDNA from total RNA was subsequently diluted 100 
fold and the human miRCURY (Human Panel I+II, V2.M) Ready-to-Use PCR array 
(Exiqon) consisting of 748 miRNAs, was used for the expression profile of circulatory 
miRNA in both portion of follicular fluid and blood plasma. The qPCR data was 
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analyzed using a comparative threshold cycle (∆CT) method after normalization by 
global normalization method. To minimize potential noise, miRNAs with a Ct value of 
> 35 were filtered out. Subsequent expression profiling of miRNA was performed using 
the human miRCURY LNA™ Universal RT miRNA PCR array platform with 745 
miRNA primer assays. Of the 24 miRNAs, which were differentially expressed in blood 
plasma between hyperstimulated and unstimulated animals, 9 miRNAs including miR-
127-3p, miR-494, miR-147, miR-134 and miR-153 were down regulated and 15 
miRNAs including miR-34a, miR-103, let-7g, miR-221 were found to be up regulated 
in the hyperstimulated  animals. Similarly, 66 miRNAs were found to be differentially 
expressed in follicular fluid derived from hyperstimulated and unstimulated groups. Out 
of these, while 32 miRNAs, were down regulated, while 34 were up regulated in 
follicular fluid aspirated from hyperstimulated animals.  
 
To determine the extent to which circulatory miRNAs are associated with exosomes in 
follicular fluid and blood plasma on day 7 we used differential ultracentrifugation to 
purify circulating exosomes from cell free, platelet-poor follicular fluid and blood 
plasma at day 7 prepared from same animals. To determine if Ago 2 proteins are present 
in plasma, we performed immunoprecipitation followed by Ago2 protein blotting. By 
using quantitative RT-PCR, we assayed expression levels of a candidate set of miRNAs 
in the vesicle pellets and the immunoprecipitated Ago2 for well characterized 
circulating miRNAs of follicular fluid and blood plasma in hyperstimulated and 
unstimulated heifers. To evaluate the expression of the selected miRNAs we examined 
temporal changes in expression levels of a candidate set of miRNAs in blood plasma at 
day 0, 3 and 7 the onset of oestrus of hyperstimulated as compared to unstimulated in 
normal conditions.   
 
Ingenuity pathway analysis (IPA) of potential target genes of candidate miRNAs, which 
were dysregulated due to ovarian hyperstimulation, revealed that the genes targeted by 
the miRNAs were mainly involved in PTEN  signaling , neurotrophin signaling 
pathway, and HGF signaling pathway, VEGF signaling pathway, TGF-β signaling 
pathway, axonal guidance signaling and Wnt ß-catenin signaling pathways to be the 
dominant ones. 
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In conclusion, the present study reported for the first time bovine ovarian 
hyperstimulation to induce changes in expression profiles of circulatory miRNA 
coupled with exosomes or non-exosomes structures (i.e. Ago2, HDL) in follicular fluid 
and blood. This data highlight a number of differentially expressed circulatory miRNAs 
in bovine follicular fluid and blood plasma in relation to oocyte development 
competence and early bovine embryo development. Moreover, this dissertation also 
documented the expression profile of circulatory miRNA in follicular fluid and blood 
which considers the extra cellular miRNA role in the cell-cell communication. Our 
result is basis of the hypothesis that circulatory miRNA affect development competence 
of oocyte and early bovine embryo development. Although this data open a new area of 
extra-cellular miRNA research regarding microenvironment such as follicular and 
oviductal fluid, in-depth functional studies will be required to understand the functional 
contribution of differentially expressed miRNAs to acquire follicular and early embryo 
development under supraphysiological levels of gonadotropins. 
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7 Zusammenfassung  
 
 
Durch eine kontrollierte ovarielle Hyperstimulation (COH) der Eierstöcke mittels eines 
supraphysiologischen Gonadotropin-Spiegels wird das Wachstum mehrerer Follikel 
angeregt. Wertvolle Zuchtrinder werden ebenfalls mit Gonadotropin stimuliert um ihre 
Nachkommenzahl zu erhöhen. Fortschritte wurden bei der Superovulation und der 
Anwendung wenig invasiver Methoden bei der Embryogewinnung und dem Transfer 
sowie bei der Embryo-Tiefgefrierung gemacht. Doch trotz des erheblichen Fortschritts 
in den assistierten Reproduktionstechnologien beim Mensch und Rind, sind die 
Entwicklungsraten relativ niedrig und haben nicht wesentlich in den letzten zehn Jahren 
zugenommen. 
 
MicroRNAs (miRNAs) sind Posttranskriptionsregulatoren, die die Expression von 
hunderten von Genen in zahlreichen biologischen Prozessen, einschließlich der 
Entwicklung, beeinflussen. Zirkulierende nicht-kodierende miRNAs sind in 
verschiedenen Körperflüssigkeiten vorhanden und können möglicherweise potenzielle 
Biomarker für Krankheiten und Trächtigkeiten sein. Die vorliegende Studie wurde 
durchgeführt, um die Wirkung einer ovarialen Hyperstimulation auf das 
Expressionsmuster von zirkulierenden miRNAs in der Follikelflüssigkeit und im 
Blutplasma zu untersuchen. Dazu wurden Fleckvieh-Färsen (n = 12) mit einem 
Standard-Synchronisationsprotokoll synchronisiert und sechs von ihnen mit FSH 
hyperstimuliert. Die Probenentnahme beinhaltete Blutproben zum Zeitpunkt 0 (Beginn 
der Brunst), am 3. und am 7. Tag sowie die Entnahme von Follikelflüssigkeit von 
dominanten Follikeln am Tag 0 von allen Tieren durch Ovum pickup. 
 
Die Gesamt-RNA Isolierung erfolgte mit dem miRNeasy ® Mini-Kit. 100 ng Gesamt-
RNA aus der Follikelflüssigkeit und dem Blutplasma wurden mit dem Universal cDNA-
Synthese-Kit transkribiert. Die resultierende cDNA wurde anschließend 100-fach 
verdünnt. Mittels des Human miRCURY (Human Panel I + II, V2.M) Ready-to-Use-
PCR-Array (Exiqon), bestehend aus 748 miRNAs, wurde von den zirkulierenden 
miRNAs aus der Follikelflüssigkeit und dem Blutplasma ein Expressionsprofil erstellt. 
Die Analyse der qPCR-Daten erfolgte durch einen Vergleich der Schwellenzyklen 
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(∆Ct-Methode) nach einer Normalisierung durch das globale Normierungsverfahren. 
Um mögliche Störungen zu minimieren, wurden miRNAs mit einem Ct-Wert von > 35 
herausgefiltert. 
 
Die nachfolgende Expressionprofilierung der miRNAs erfolgte unter Verwendung der 
Humanen miRCURY LNA ™ Universal- RT -PCR- miRNA -Array -Plattform mit 745 
miRNA Primer -Assays. Von den 24 miRNAs, die im Blutplasma beim Vergleich 
zwischen hyperstimulierten und unstimulierten Tiere unterschiedlich exprimiert waren, 
zeigten 9 miRNAs, einschließlich,  miR- 127- 3p, miR- 494, miR- 147, miR- 134 und 
miR -153, eine Runterregulation während 15 miRNAs einschließlich miR- 34a, miR -
103 , let- 7g, miR -221 eine erhöhte Expression  in den hyperstimulierten Tiere 
aufwiesen. Des Weiteren konnten beim Vergleich der Follikelflüssigkeit von 
hyperstimulierten und unstimulierten Tieren 66 differentiell exprimierte miRNAs 
identifiziert werden. Von diesen waren 32 miRNAs herunterreguliert, während 34 in der 
Gruppe der hyperstimulierten Tiere raufreguliert waren. 
 
Um das Ausmaß der Assoziation der zirkulierenden miRNAs mit Exosomen aus 
Follikelflüssigkeit und Blutplasma an Tag 7 festzustellen, wurde mittels 
Dichtegradientenzentrifugation von denselben Tieren die zirkulierenden Exosomen von 
der zellfreien, plättchenarmen der Follikelflüssigkeit und dem Blutplasma  am Tag 7 
gereinigt. Um festzustellen ob Ago 2 Proteine im Plasma vorhanden sind, führten wir 
eine Immunpräzipitation durch, dieser folgte ein Ago 2 Protein –Blot. Mittels 
quantitativer RT-RCR analysierten wir eine Reihe gut charakterisierter miRNAs aus 
Follikelflüssigkeit und Blutplasma in hyperstimulierten und unstimulierten Färsen. 
Temporale Expressionsprofile der miRNAs wurden an den Tagen 0, 3 und 7 des Zyklus 
zwischen stimulierten und unstimulierten Färsen erhoben und verglichen. Die 
Ergebnisse zeigten signifikante Expressionsveränderungen der meisten miRNAs 
zwischen den verschiedenen Zyklustagen, während innerhalb der gleichen Zyklustage 
ähnliche Expressionsmuster zwischen stimulierten und unstimulierten Färsen zu 
beobachten waren. Lediglich miR-32 war am Tag 3 bei unstimulierten Färsen im 
Vergleich zu hyperstimulierten herunterreguliert. Eine Ingenuity Pathway Analyse 
(IPA) der potentiellen Zielgene von Kandidaten miRNAs, die aufgrund von 
Hyperstimulation der Ovarien eine Fehlregulation zeigten,  ergab als dominante 
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Signalwege die PTEN Signalisierung, den Neurotrophin Signalweg, den HGF 
Signalweg, den VEGF Signalweg, den TGF-ß Signalweg sowie den Wnt-ß-Catenin 
Signalweg.  
 
Die Ergebnisse der vorliegenden Studie berichten zum ersten Mal über die 
Veränderungen der Expressionsprofile von zirkulierenden miRNAs aus der 
Follikelflüssigkeit und dem Blutplasma von Rindern mit einer induzierten 
Hyperstimulation der Ovarien sowie von einer möglichen Kopplung der zirkulierenden 
miRNAs mit Exosomen oder nicht Exosomen Strukturen (z.B. Ago 2, HDL). Es wurden 
eine Reihe von differenziell exprimierten zirkulierenden miRNAs  in Follikelflüssigkeit 
und Blutplasma in Bezug auf die Entwicklungskompetenz der Eizelle und frühen 
Rinderembryoentwicklung identifiziert. Diese Dissertation dokumentiert das 
Expressionsprofil extrazellulärer zirkulatorischer miRNAs in Follikelflüssigkeit und 
Blut. Die Daten unterstützen die Hypothese, dass miRNAs sowohl an der Oozyten- als 
auch der frühen Embryonalentwicklungskompetenz beteiligt sind. Weitergehende 
funktionelle Unternehmungen werden notwendig sein, um die an dem Follikelwachstum 
unter Hyperstimulationsbedingungen beteilige Genregulation näher abzuklären.
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